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Structure-Activity Investigations 
and Optimisations of Non-
metabolite Agonists for the 
Succinate Receptor 1
Elisabeth Rexen Ulven  1, Mette Trauelsen2, Matjaz Brvar1, Michael Lückmann3, 
Line Ø. Bielefeldt1, Lisa K. I. Jensen1, Thue W. Schwartz2,3 & Thomas M. Frimurer2
The succinate receptor 1 (SUCNR1) is a receptor for the metabolite succinate, which functions as 
a metabolic stress signal in the liver, kidney, adipose tissue and the retina. However, potent non-
metabolite tool compounds are needed to reveal the physiological role and pharmacological potential 
of SUCNR1. Recently, we published the discovery of a computationally receptor-structure derived non-
metabolite SUCNR1 agonist series with high target selectivity. We here report our structure-activity 
exploration and optimisation that has resulted in the development of agonists with nanomolar potency 
and excellent solubility and stability properties in a number of in vitro assays. Ligand-guided receptor 
models with high discriminative power between binding of active and inactive compounds were 
developed for design of novel chemotypes.
The 7-transmembrane G-protein coupled receptor SUCNR1 was first identified in 2001 and found to have close 
homology with the purinergic receptor P2Y1. The receptor was therefore initially believed to be activated by 
purinergic compounds1. However, in 2004, SUCNR1 was deorphanised and found to be activated by the citric 
acid cycle intermediate succinate at micromolar concentrations2. The other citric acid cycle intermediates oxalo-
acetate and α-ketoglutarate were also found to activate the receptor, albeit with reduced potency3,4. SUCNR1 is 
highly expressed in liver, kidney, and adipose tissue, but has also been reported in retina, heart, and immune 
cells2,5–7. During oxidative stress succinate can accumulate and reach local concentrations sufficiently high to 
activate SUCNR18, leading to a variety of unwanted physiological effects such as hypertension2, hypertrophy of 
the heart7, inflammation9, inhibition of lipolysis in the white adipose tissue5, activation of hepatic stellate cells10, 
and vascular growth in the retina6.
Although most studies so far indicate that antagonists for SUCNR1 might be optimal from a therapeutic 
perspective this has yet to be experimentally confirmed and is mainly based on studies using the natural agonist 
succinate, a compound that beside its relatively weak potency also is an intermediate in the citric acid cycle and 
exerts effects unrelated to SUCNR1. In 2011, the first and so far only antagonists for SUCNR1 were reported, con-
sisting of a series of naphthyridines that demonstrated good pharmacokinetic properties in rats11. Small synthetic 
succinate analogues have recently been reported as full agonists and although the compounds show improved 
agonistic potency, the best compound, cis-epoxysuccinic acid, has an EC50 of only 2.7 μM3.
Based on the characterisation of the binding site for succinate in SUCNR1 and identification of an empty 
side-pocket in the receptor, we have recently published the discovery of novel drug-like SUCNR1 agonists which 
in accordance with both loss- and gain-of-function mutational data exploited this pocket4. Here we report the 
further development and structure-activity investigations of this agonist series. The generated library of active 
and inactive compounds together with the original receptor model based on the X-ray structure of the P2Y1 
receptor allowed for generation of new SUCNR1 models which could discriminate between active and inactive 
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compounds with high discriminative power. Although the human and mouse receptor orthologues are closely 
related they are not identical and succinate shows a small increase in potency on the mouse receptor2. All com-
pounds have therefore been studied on both the human and mouse orthologues in order to develop tool com-
pounds for further investigations of SUCNR1.
Results and Discussion
Synthesis. All test compounds were synthesised by the same overall route, starting from L-aspartic acid (1) 
that was converted to the corresponding dimethyl ester hydrochloride 2 by an acid catalysed esterification (Fig. 1). 
Coupling of 2 to various carboxylic acids was efficiently achieved via the corresponding acyl fluoride generated 
in situ by fluoro-N,N,N’,N’-bis(tetramethylene)foramidinium hexafluorophosphate (BTFFH)12. Halogenated aryl 
and heteroaryl compounds were coupled with various aryl boronic acids by a Suzuki reaction using the 4th gen-
eration Pd-XPhos precatalyst. The phenolic compounds were afterwards alkylated by alkylhalides or –tosylates. 
Finally, base promoted hydrolysis using LiOH gave the desired dicarboxylic acid test compounds.
Exploration of structure activity relationship (SAR). In order to optimise the activity of the lead com-
pound Cmpd (S)−130 (3), we started by exploring larger modifications of the aromatic part of the molecule 
(selected examples are included in Table 1). Initially, the aromatic part was truncated by exchanging the fluoro-
phenyl with a bromine (4), which resulted in more than one order of magnitude decrease in potency. Exchanging 
the bromofurane with the halogenated phenyls 5–7 revealed weak activity on both receptor orthologues of the 
ortho-chlorine and para-bromine analogs. Only the larger meta-iodine substituted compound 6 showed micro-
molar activity on both receptor orthologues. Inserting a methylene-linker between the amide and the bromophe-
nyl (8) resulted in an inactive compound and exchanging the bromine for the fluorophenyl (9) only gave a weakly 
active compound, far less potent than the lead 3.
Since the smaller compounds did not show sufficient activity we moved the focus to explorations on the 
terminal phenyl ring (Table 2). Initially, the original 4-fluoro substituent was removed (10). This only affected 
the potency marginally on both receptor orthologues, but exposes a potential metabolically labile site. Next, a 
methyl scan of the ring was performed to investigate the binding site for additional space (11–13). Whereas both 
the ortho- and meta-methyl were tolerated only the para-methyl 13 led to a more potent compound on both 
human and mouse SUCNR1. Attempts to pick up hydrogen bond interactions revealed that 2-methoxy (16) was 
equivalent to the 2-methyl in potency and that 3-hydroxymethyl (14) was less tolerated than the 3-methyl (12) 
with a 3-fold decrease in potency. Again, the para-position was favoured with the 4-hydroxy (15) being almost 
equipotent with the 4-methyl compound. Further exploration of the para-position indicated that this part of the 
binding pocket is able to accommodate polar substituents such as methoxy (17) and nitrile (19) as well as non-
polar substituents such as trifluoromethyl (18), all showing similar potencies in the submicromolar range on the 
human receptor orthologue and with 17 slightly favoured on the mouse orthologue.
To further explore the 4-methoxy compound, the most potent analogue on the mouse receptor, a sub series 
of para-alkoxy analogues were investigated (Table 3). The larger and more electronegative trifluoromethoxy (20) 
showed a 2-fold increase on hSUCNR1 but was accompanied by >4-fold decrease on mSUCNR1, rendering the 
compound approximately equipotent on both orthologues. Expanding to either ethoxy (21) or i-propoxy (22) 
resulted in a small increase in potency, indicating that the binding pocket can accommodate more elongated and 
bulky substituents. To explore whether or not the binding site could also accommodate larger hydrophilic sub-
stituents the oxatane 23 was investigated and found tolerable, but led to >2-fold reduction of potency. Finally, the 
mesylpropoxy analogue 24 was explored. This appendage, which lowers the lipophilicity an order of magnitude, 
has previously been applied to lower lipophilicity of ligands for the free fatty acid receptor FFA1 and has proven 
to be a metabolically stable substituent13,14. Lipophilicity of this compound is in the low end of the desired range 
Figure 1. General synthetic route. Reagents and conditions: (a) SOCl2, MeOH, 0 °C → reflux. (b) BTFFH, 
DIPEA, ArCOOH, DCM, 80 °C. (c) ArB(OH)2, Pd-XPhos-G4, 0.5 M K3PO4aq, THF, room temp. (d) For 
R” = OH: K2CO3, alkylhalide/tosylate, MeCN, 50–55 °C. (e) 0.6 M LiOHaq, THF, room temp.
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but it is interesting to note that the compound exhibited a ligand lipophilicity efficiency (LLE) >5 based on ClogP 
and almost sustained potency on both mSUCNR1 and hSUCNR1.
Subsequently, the attention was directed towards the central aromatic ring (Table 4). Replacing the furane 
of 3 with the 1,3-substituted phenyl 25 improved the potency somewhat on the human orthologue whereas the 
potency on the mouse orthologue decreased 10-fold. The 1,4-substituted phenyl 26 clearly led to an unfavoured 
geometry with only trace activity on SUCNR1. The corresponding 2,6-substituted pyridine 27 sustained the 
potency on hSUCNR1 and almost regained the potency on mSUCNR1.
Next, a small selection of compounds was synthesised to combine the observed SAR of the alkoxy-substituents 
and alterations of the central ring (Table 5). The 4-methoxy and 4-trifluoromethoxy substituents, being the most 
potent alkoxy-substituents on the mouse and human receptor orthologues, respectively, were attached to com-
pounds bearing the 1,3-substituted phenyl and the 2,6-substituted pyridine as the central ring. No improvement 
was observed for the methoxy analogues (28–29). In contrast, the trifluoromethoxy analogues (30–31) were 
found to be the most potent compounds on hSUCNR1, but unfortunately without high potency on mSUCNR1, 
especially for 30. The elongated trifluoroethoxy analogue 32 showed improved potency on the mouse ortho-
logue. Still, 31 remained the most potent agonist on hSUCNR1. Finally, the 4-propoxy analogue 33 was found 
to be approximately twice as potent as the corresponding methoxy analogue 29 and almost equipotent on both 
orthologues.
To get a better overview of the observed SAR on the human and mouse receptor orthologues a scatterplot 
of all active compounds was made (Fig. 2a). The compounds were color-coded according to the central or ter-
minal ring, which clearly indicated that compounds with a central meta-substituted phenyl were better toler-
ated on hSUCNR1. The 2,6-substituted pyridines were in general more potent and especially 31 was favoured 
on hSUCNR1. Compounds with a furane as central ring were in general equipotent on the two receptor ort-
hologues, but with addition of a phenalkoxy moiety, the compounds became more potent on mSUCNR1 with 
21 being the most potent. Furthermore, dose-response curves of succinate, 3, 21, and 31 clearly showed that 
the non-metabolite compounds were partial agonists, with clear species differences on potency but not efficacy 
(Fig. 2b,c). The partial agonism was observed for all agonistic compounds (Tables 1–5, Supplementary Fig. S1).
Molecular modelling and unbiased ligand guided refinement of SUCNR1 receptor-ligand com-
plexes. To describe the detailed molecular mechanism of action and to rationalise the structure-activity data, 
R
hSUCNR1 mSUCNR1
ClogPbpEC50 (efficacy, %)a
3 5.75 ± 0.08 (72.8 ± 2.6) 6.46 ± 0.06 (79.3 ± 1.6) 1.66
4 4.53 ± 0.13 (78.1 ± 7.5) 4.93 ± 0.05 (95.8 ± 2.9) 0.44
5 22% @10−4M 13% @10−4M 0.28
6 50% @10−4M 64% @10−4M 1.52
7 8% @10−4M 15% @10−4M 1.26
8 5% @10−4M 11% @10−4M 1.28
9 25% @10−4M 15% @10−4M 2.44
Table 1. Investigation of miscellaneous amide analogues. apEC50 values were determined from dose-response 
curves of induction of IP3 turnover in SUCNR1 transfected HEK cells (N = 3), efficacy is determined relative 
to succinate (100%). bCalculated by BioByte’s algorithm as implemented in ChemDraw Professional 16.0.1.4 
(ClogP option).
www.nature.com/scientificreports/
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we docked the compounds in Tables 1–5 to a model of SUCNR1 in complex with the lead compound (3) sup-
ported by a dozen of site directed mutagenesis data as presented earlier4. Despite that we observed binding con-
formations similar to the lead and with favourable scores, the model - as perhaps could be expected - was unable 
to rank the compounds in reasonable agreement with the activity data. The interpretation of SAR and struc-
ture based design reaches its maximum potential when the receptor displays the structural changes needed for 
ligand binding, as it has previously been shown in a blind prediction assessment of adenosine A2a receptor com-
plexes (GPCR Dock 2008)15–18. We therefore applied an iterative Automated Ligand-guided Backbone Ensemble 
Receptor Optimisation protocol (ALiBERO)19, which samples full receptor and ligand flexibility guided by the 
ligand information gained in this study to validate and build confidence in the model.
In brief, starting from the homology model supported by mutagenesis data4, ALiBERO introduced receptor 
flexibility via Normal Mode Analysis and Monte Carlo sampling, to generate a small subset of receptor mod-
els (pockets). All compounds tested in this study were grouped into an active (EC50 ≤ 10 µM) and a decoy set 
(EC50 > 10 µM) consisting of 25 compounds each. For a list of all compounds used in the optimisation protocol, 
see Table S1. Receptor structures were then chosen based on their ability to discriminate actives from inactives 
Ring A
hSUCNR1 mSUCNR1
ClogPbpEC50 (efficacy, %)a
3c 5.75 ± 0.08 (72.8 ± 2.6) 6.46 ± 0.06 (79.3 ± 1.6) 1.66
10 5.29 ± 0.19 (81.6 ± 8.4) 6.16 ± 0.11 (81.3 ± 3.6) 1.47
11 5.27 ± 0.18 (94.7 ± 8.7) 6.13 ± 0.10 (76.7 ± 3.1) 1.67
12 5.02 ± 0.10 (91.9 ± 5.3) 6.07 ± 0.09 (81.6 ± 3.0) 1.97
13 6.33 ± 0.14 (69.1 ± 3.9) 6.83 ± 0.11 (73.2 ± 2.7) 1.97
14 4.81 ± 0.20 (74.2 ± 11.8) 5.71 ± 0.09 (79.6 ± 3.7) 0.43
15 6.13 ± 0.14 (71.1 ± 4.2) 6.82 ± 0.08 (74.8 ± 2.0) 0.87
16 5.29 ± 0.15 (103.8 ± 7.9) 6.14 ± 0.10 (78.1 ± 3.1) 0.89
17 6.41 ± 0.14 (85.3 ± 4.5) 7.39 ± 0.07 (84.2 ± 1.8) 1.45
18 6.55 ± 0.25 (81.0 ± 7.2) 6.81 ± 0.17 (80.6 ± 4.6) 2.43
19 6.39 ± 0.11 (72.1 ± 3.2) 6.79 ± 0.06 (76.0 ± 1.5) 1.00
Table 2. Investigation of ring A. apEC50 values were determined from dose-response curves of induction of 
IP3 turnover in SUCNR1 transfected HEK cells (N = 3), efficacy is determined relative to succinate (100%). 
bCalculated by BioByte’s algorithm as implemented in ChemDraw Professional 16.0.1.4 (ClogP option). 
cDuplication of data from Table 1.
www.nature.com/scientificreports/
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in a retrospective virtual screening using the docking protocol and scoring function in ICM (Molsoft L.L.C., 
San Diego, CA, USA)20, as measured by the normalised square root area under the curve (NSQ_AUC). The 
best-performing structures from the first generation were consequently selected for the next generation and the 
steps were repeated in an iterative fashion until maximum docking performance of receptor structures to enrich 
active compounds was reached. The ALiBERO-optimised receptor ensemble was subsequently validated in a 
virtual ligand screening using an external test set with a higher active:decoy ratio (~1:50).
Notably, the ligand-guided ALiBERO-based mSUCNR1 models demonstrated a dramatic improvement in ret-
rospective virtual screening performance of the developed compounds compared with the initial homology mod-
els and proved successful in separating the majority of active from inactive ligands in docking screens (Fig. 3a, 
Supplementary Fig. S2). It is interesting to note that the active ligands bind to an extended binding cavity in a very 
consistent pose compared to the lead compound (3) supported by both loss-of-function but also gain-of-function 
mutagenesis data as we have reported previously4. For example, the receptor mutants R251:6.58 L and R276:7.39 F 
showed a potency decrease of more than 100-fold. The binding cavity of SUCNR1 is characterised by a polar 
network consisting of residues in TM-II (Y79:2.64), TM-III (R95:3.29), TM-VI (R248:6.55, R251:6.58), TM-VII 
(K269:7.32, Y272:7.35, R276:7.39), ECL2 (D174) as well as a relatively hydrophobic subpocket spanning between 
TM-I, -II, ECL1 and −2 up towards the extracellular surface of the receptor (residue numbering according to 
R
hSUCNR1 mSUCNR1
ClogPbpEC50 (efficacy, %)a
17c Me 6.41 ± 0.14 (85.3 ± 4.5) 7.39 ± 0.07 (84.2 ± 1.8) 1.45
20 F3C 6.99 ± 0.15 (61.7 ± 3.6) 6.72 ± 0.11 (69.7 ± 2.8) 3.17
21 Et 6.59 ± 0.14 (56.3 ± 3.1) 7.44 ± 0.09 (70.2 ± 2.0) 1.98
22 iPr 6.84 ± 0.14 (69.6 ± 4.3) 7.29 ± 0.07 (75.6 ± 1.7) 2.29
23 6.27 ± 0.11 (76.5 ± 3.1) 6.97 ± 0.07 (82.4 ± 1.9) 1.81
24 6.10 ± 0.09 (63.9 ± 2.4) 7.33 ± 0.09 (74.6 ± 2.1) 0.53
Table 3. Alkoxy analogues. apEC50 values were determined from dose-response curves of induction of IP3 
turnover in SUCNR1 transfected HEK cells (N = 3), efficacy is determined relative to succinate (100%). 
bCalculated by BioByte’s algorithm as implemented in ChemDraw Professional 16.0.1.4 (ClogP option). 
cDuplication of data from Table 2.
Ring B
hSUCNR1 mSUCNR1
ClogPbpEC50 (efficacy, %)a
3c 5.75 ± 0.08 (72.8 ± 2.6) 6.46 ± 0.06 (79.3 ± 1.6) 1.66
25 5.91 ± 0.11 (49.7 ± 3.9) 5.40 ± 0.13 (58.0 ± 4.5) 2.27
26 4% @10−4M 7% @10−4M 2.27
27 6.03 ± 0.25 (78.2 ± 8.0) 6.10 ± 0.17 (89.3 ± 6.1) 2.05
Table 4. Investigation of ring B. apEC50 values were determined from dose-response curves of induction of 
IP3 turnover in SUCNR1 transfected HEK cells (N = 3), efficacy is determined relative to succinate (100%). 
bCalculated by BioByte’s algorithm as implemented in ChemDraw Professional 16.0.1.4 (ClogP option). 
cDuplication of data from Table 1.
www.nature.com/scientificreports/
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gpcrdb.org). The optimised receptor ensemble (Fig. 3b) accommodates the active compounds in a common bind-
ing mode in which the left-hand side carboxylic acids make hydrogen bond interactions with R95:3.29, R251:6.58 
and R276:7.39 and where the right-hand side of the ligands adopts an angled conformation that is defined by 
the linker between ring A and B in good agreement with the observed structure-activity relationship. Due to the 
Ring A Ring B
hSUCNR1 mSUCNR1
ClogPbpEC50 (efficacy, %)a
28 6.79 ± 0.12 (58.0 ± 2.7) 5.92 ± 0.09 (64.0 ± 2.5) 2.01
29 6.85 ± 0.19 (52.6 ± 3.9) 6.74 ± 0.13 (71.2 ± 3.2) 1.07
30 7.23 ± 0.14 (49.2 ± 2.7) 5.84 ± 0.16 (45.3 ± 3.4) 3.11
31 7.64 ± 0.13 (61.7 ± 2.5) 6.75 ± 0.09 (69.9 ± 2.2) 2.18
32 7.23 ± 0.23 (88.7 ± 6.1) 7.00 ± 0.09 (68.1 ± 2.5) 1.86
33 7.23 ± 0.37 (66.4 ± 7.2) 7.29 ± 0.18 (61.5 ± 3.8) 2.13
Table 5. Combined analogues. apEC50 values were determined from dose-response curves of induction of 
IP3 turnover in SUCNR1 transfected HEK cells (N = 3), efficacy is determined relative to succinate (100%). 
bCalculated by BioByte’s algorithm as implemented in ChemDraw Professional 16.0.1.4 (ClogP option).
Figure 2. Summary of in vitro agonist potencies. (a) Scatterplot of in vitro agonist potencies by IP3 
accumulation in SUCNR1 transfected HEK-293 cells of the compounds in Tables 1–5 on the hSUCNR1 and 
mSUCNR1 receptor. (b,c) Dose-response curves for succinate and selected compounds (3, 21 and 31) on 
hSUCNR1 and mSUCNR1.
www.nature.com/scientificreports/
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shape and direction of the subpocket accommodating ring A, compounds with a bent conformation between the 
amide and the terminal ring, e.g. compounds having 2,5-substitued furan or meta-substituted phenyl as central 
ring, are sterically better tolerated than e.g. the para-substituted phenyl 26 and elongated para-substituted phenyl 
9. Furthermore, compounds with a pyridine (e.g. 27, 29, 31), or furan as central ring, can stabilise the favoured 
bent conformation by intramolecular hydrogen bonding between the pyridine nitrogen or furan oxygen and the 
amide N-H, thereby inducing an optimal low energy conformation.
The subpocket that is occupied by ring A, contains W10:1.42 which allows for parallel displaced aromatic 
stacking interactions that are present in all binding poses for the active ligands. As this pocket spans all the way 
to the extracellular tips of TM-I and -II, it is able to accomodate longer substituents, such as the mesylate 24 
(Fig. 3b), which likely interacts with solvent water molecules on the extracellular surface of the receptor cavity. 
Compounds that contain O-alkyl, hydroxyl, or nitrile groups in the para-position on ring A, such as 15, 17, 19–24 
and 28–31, can form hydrogen bond interactions with K83 (Asn87 in hSUCNR1) and backbone NH of Glu170 
in ECL1 and −2b (Fig. 3c). Due to the geometry of this interaction, ortho- and meta-subtitutions (14 + 16) are 
less favorable.
While the polar residues that coordinate the dicarbocylic acid moiety are highly conserved between mouse 
and human SUCNR1, the hydrophobic subpocket accommodating ring A is more diverse with several differ-
ences in ECL1 (Lys83/Asn87), ECL2 (Lys162/Thr166, Glu163/Asp166, Glu164/Asn166, Asn167/Thr171) and 
TM-VII (Lys269/Asn274) between mSUCNR1 and hSUCNR1, respectively. The Lys83/Asn87 difference between 
mSUCNR1 and hSUCNR1 might explain the higher potencies of the trifluoromethoxy-substituted compounds 
30 and 31 on hSUCNR1, as these bulky moities likely form more favorable interactions with the shorter Asn 
side-chain (Fig. 3c).
In conclusion, the developed ligand-guided SUCNR1 models are consistent with the SAR, and they are suffi-
ciently accurate to separate actives from decoys, suggesting that the models will be valuable in prospective studies 
to support structure-based drug design of additional chemotypes directly related to drug discovery applications.
Physicochemical and in vitro stability properties. Based on the SAR exploration, the original lead (3) 
and the most potent agonists on hSUCNR1 (31) and mSUCNR1 (21) were selected for further property investiga-
tions. All compounds showed excellent chemical stability (>98% after 70 hours) and kinetic solubility (>200 μM) 
in 10 mM PBS7.4. However, the high aqueous solubility made logD7.4 determinations very challenging and only the 
most lipophilic compound 31 could be quantified (logD7.4 = −2.13). The stability of the compounds was further 
Figure 3. Iterative SUCNR1 receptor optimisation based on ligand information gained in this study. (a) Small-
scale virtual ligand screening (VLS) results at different stages of the optimisation process (generations GEN_1 
- GEN_4). Receiver operating characteristic (ROC) curves and normalised square root area under the curve 
(NSQ_AUC) values are shown for each generation of receptor pockets. The diagonal corresponds to a random 
VLS performance. (b) Best-performing receptor pocket ensemble (GEN_4), consisting of three receptor 
structures shown with the best-scored docking poses of all 25 active compounds investigated in this study (dark 
green lines). Best-scored docking poses of compound 24 (b), 31 (c), 3 (d) and 21 (e) are shown in green sticks. 
Polar receptor-ligand interactions are indicated by yellow spheres. Homology models are based on the x-ray 
crystal structure of the P2Y1 receptor (PDB 4XNW) which shares several key side-chains in the binding site 
with SUCNR1, i.e. Y79:2.64, D174 and R276:7.39. Figure was made using PyMol.
www.nature.com/scientificreports/
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examined in a selection of simulated gastrointestinal fluids (FaSSGF, FaSSIF and FeSSIF) and all compounds were 
found to be stable for 2 hours, with exception of 31 in FeSSIF, which could not be determined due to overlapping 
UV-absorption of the compound and media. Finally, the stability in mouse liver microsomes was investigated and 
all compounds were found to be stable for 1 hour, possibly partly due to the hydrophilic nature of the compounds.
Conclusion
We here report the structure-activity investigations of a series of non-metabolite SUCNR1 agonists that was orig-
inally identified from a computational, receptor-structure derived agonistic lead. ALiBERO optimised homology 
models of the mouse SUCNR1 were developed based on the x-ray structure of the closely related P2Y1 recep-
tor and found to be sufficiently accurate to discriminate between actives and inactives and could explain the 
majority of the SAR observations. The exploration led to development of potent drug-like, non-metabolite tool 
compounds with nanomolar potency on both the human and murine receptor orthologues and excellent physic-
ochemical and in vitro stability properties. We believe these compounds will be useful for further investigations 
of SUCNR1 as a potential therapeutic target and pharmacokinetic studies in mice are currently ongoing and will 
reveal if absorption of the compounds might be challenged by their hydrophilic nature and if the excellent stabil-
ity properties are conserved in vivo.
Methods
General. Commercial starting materials and solvents were used without further purification, unless otherwise 
stated. THF was freshly distilled from sodium/benzophenone. DCM was distilled and stored over 3 Å sieves. 
MeCN and N,N-diisopropylethylamine were dried over 3 Å sieves. K2CO3 was dried and stored in an oven. TLC 
was performed on TLC silica gel 60 F254 plates and visualised at 254 or 365 nm or by staining with phosphomo-
lybdic acid, ninhydrin, or KMnO4 stains. Purification by flash chromatography was carried out using silica gel 60 
(0.040–0.063 mm, Merck). 1H and 13C NMR spectra were recorded at 400 and 101 MHz, respectively, on a Bruker 
Avance III 400 at 300 K. Spectra were calibrated relative to the internal standard TMS or residual solvent peak: 
CDCl3 (δC = 77.16 ppm, δH = 7.26 ppm), DMSO-d6 (δC = 39.52 ppm, δH = 2.50 ppm) and acetone-d6 (δC = 29.84 
ppm, δH = 2.05 ppm).
HPLC analysis was performed using a Gemini C18 column (5 μm, 4.6 × 150 mm); flow: 1 mL/min; 10% MeCN 
in water (0–1 min), 10–100% MeCN in water (1–10 min), 100% MeCN (11–15 min), with both solvents con-
taining 0.1% HCOOH as modifier; UV detection at 254 nm (or 280 nm, 304 nm and 315 nm depending on test 
compound absorption maximum for solubility and stability studies). UPLC analysis was performed using a 100 Å 
C18 column (1.7 μm, 2.1 × 100 mm); flow: 0.3 mL/min; 70% MeOH in water (0–6 min), the water containing 
0.1% HCOOH as modifier; UV detection at 254 nm, 280 nm, 304 nm or 315 nm depending on test compound 
absorption maximum. High-resolution mass spectra (HRMS) were obtained on a Bruker micrOTOF-Q II (ESI). 
Optical rotation was measured on an Anton Paar MCP 100 Polarimeter (Anton Paar Cell 100 mm, CL. 0.01, Ø 
5 mm). Purity was determined by HPLC (254 nm) and confirmed by inspection of NMR spectra. The purity of all 
test compounds were >95%.
Amide coupling. An oven dried microwave vial under argon atmosphere was charged with the acid (1.3 
equiv), dry DCM (2 mL/mmol), N,N-diisopropylethylamine (5.5 equiv) and BTFFH (1.5 equiv). The reaction 
mixture was stirred at rt for 30 min before the HCl salt of the amine (1 equiv) was added. After addition, the vial 
was capped and heated to 80 °C overnight. The reaction was cooled to rt and diluted with water and extracted with 
EtOAc (x3). The organic phases were combined, washed with brine, dried over Na2SO4 and concentrated in vacuo. 
The residue was purified by flash column chromatography (SiO2, EtOAc:petroleum ether).
Suzuki coupling. A schlenck flask under argon was charged with boronic acid (1.1 equiv), aryl/pyridyl halide 
(1 equiv) and Pd-XPhos-G4 (2 mol%). The flask was evacuated and backfilled with argon (x3). THF (5 mL/mmol) 
and aqueous 0.5 M K3PO4 (2 equiv) was added, and the reaction was stirred at rt. After completion, the reaction 
mixture was diluted with water and extracted with EtOAc (x3). The organic phases were combined, washed with 
brine, dried over Na2SO4 and concentrated in vacuo. The residue was purified by flash column chromatography 
(SiO2, EtOAc:petroleum ether).
Alkylation. The phenol (1 equiv) was dissolved in dry MeCN (~6 mL/mmol) in a dry vial under argon atmos-
phere. The alkyl halide/tosylate (2–7 equiv) and dry K2CO3 (2 equiv) were added and the reaction was stirred at 
50–55 °C until consumption of the phenol as monitored by TLC. After completion, the reaction was diluted with 
water and extracted with EtOAc (x3). The organic phases were combined, washed with brine, dried over Na2SO4, 
and concentrated in vacuo. The residue was purified by flash column chromatography (SiO2, EtOAc:petroleum 
ether).
Ester hydrolysis. The ester (1 equiv) was dissolved in THF (~6 mL/mmol), and aqueous 0.6 M LiOH (3 
equiv) was added. The reaction was stirred at rt until consumption of the ester as monitored by TLC. After com-
pletion, the reaction was diluted with water, acidified with aqueous 1 M HCl and extracted with EtOAc (x3). The 
organic phases were combined, washed with brine, and dried over Na2SO4. The residue was concentrated in vacuo 
to give the pure title compounds.
(5-Bromofuran-2-carbonyl)-L-aspartic acid (4). Dimethyl (5-bromofuran-2-carbonyl)-L-aspartate 
(4e) was synthesised from 5-bromo furoic acid (126 mg, 0.66 mmol) and 2 (100 mg, 0.51 mmol) according to the 
general amide coupling procedure. Purification by flash column chromatography (EtOAc:petroleum ether, 1:2) 
gave 136 mg (81%) of a yellow oil: Rf = 0.30 (EtOAc:petroleum ether, 1:1); 1H NMR (400 MHz, CDCl3) δ 7.29 (d, 
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J = 7.9 Hz, 1H), 7.09 (d, J = 2.5 Hz, 1H), 6.45 (d, J = 3.5 Hz, 1H), 5.02 (dt, J = 8.6, 4.5 Hz, 1H), 3.80 (s, 3H), 3.73 (s, 
3H), 3.13 (dd, J = 17.3, 4.5 Hz, 1H), 2.94 (dd, J = 17.3, 4.5 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 171.4, 170.8, 
156.8, 148.9, 125.1, 117.3, 114.2, 53.0, 52.1, 48.3, 36.1; ESI-HRMS: calcd for C11H12BrNNaO6 (M + Na)+ 355.9740, 
found 355.9757; [α]20D − 16.5° (c 0.2, MeOH).
4 was synthesised from 4e (35 mg, 0.10 mmol) according to the general ester hydrolysis procedure to give 
28 mg (88%) of a white solid: tR = 7.68 min (HPLC); 1H NMR (400 MHz, Acetone-d6) δ 7.91 (d, J = 7.9 Hz, 1H), 
7.13 (d, J = 3.5 Hz, 1H), 6.67 (d, J = 3.5 Hz, 1H), 5.02–4.94 (m, 1H), 3.02 (d, J = 5.8 Hz, 2H); 13C NMR (101 MHz, 
Acetone-d6) δ 172.4, 172.3, 157.4, 150.7, 125.2, 117.4, 115.1, 49.4, 36.4; ESI-HRMS calcd for C8H9BrNNaO6 
(M + Na)+ 327.9427, found 327.9431; [α]20D + 7.2° (c 0.2, MeOH).
(2-Chlorobenzoyl)-L-aspartic acid (5). Dimethyl (2-chlorobenzoyl)-L-aspartate (5e) was synthesised 
from 2-chlorobenzoic acid (103 mg, 0.66 mmol) and 2 (99 mg, 0.50 mmol) according to the general amide 
coupling procedure. Purification by flash column chromatography (EtOAc:petroleum ether, 1:1) gave 121 mg 
(80%) of a pale yellow solid: Rf = 0.65 (EtOAc); 1H NMR (400 MHz, CDCl3) δ 7.70–7.66 (m, 1H), 7.44–7.30 (m, 
3H), 7.25–7.23 (m, 1H), 5.11–5.05 (m, 1H), 3.80 (s, 3H), 3.70 (s, 3H), 3.19–2.98 (m, 2H); 13C NMR (101 MHz, 
CDCl3) δ 171.6, 171.0, 166.2, 134.4, 131.8, 131.2, 130.5, 130.4, 127.2, 53.1, 52.2, 49.3, 36.2; ESI-HRMS calcd for 
C13H14ClNNaO5 (M + Na)+ 322.0453, found 322.0461; [α]20D − 22.5° (c 0.2, MeOH).
5 was synthesised from 5e (25 mg, 0.08 mmol) according to the general ester hydrolysis procedure to give 
22 mg (97%) of a white solid: tR = 7.34 min (HPLC); 1H NMR (400 MHz, Acetone-d6) δ 10.80 (br s, 2H), 7.88–7.80 
(m, 1H), 7.60–7.55 (m, 1H), 7.50–7.44 (m, 2H), 7.44–7.36 (m, 1H), 5.08–4.98 (m, 1H), 3.09–2.96 (m, 2H); 13C 
NMR (101 MHz, Acetone-d6) δ 172.3, 172.2, 166.9, 136.8, 132.1, 131.6, 130.8, 130.4, 127.9, 50.0, 36.4; ESI-HRMS 
calcd for C11H9ClNO5 (M − H)− 270.0175, found 270.0177; [α]20D + 2.0° (c 0.2, MeOH).
(3-Iodobenzoyl)-L-aspartic acid (6). Dimethyl (3-iodobenzoyl)-L-aspartate (6e) was synthesised from 
3-iodobenzoic acid (161 mg, 0.65 mmol) and 2 (99 mg, 0.50 mmol) according to the general amide coupling 
procedure. Purification by flash column chromatography (EtOAc:petroleum ether, 1:1) gave 164 mg (84%) of a 
pale yellow sticky oil: Rf = 0.33 (EtOAc:petroleum ether, 1:1); 1H NMR (400 MHz, CDCl3) δ 8.17–8.12 (m, 1H), 
7.88–7.83 (m, 1H), 7.78–7.72 (m, 1H), 7.22–7.14 (m, 2H), 5.08–4.98 (m, 1H), 3.80 (s, 3H), 3.71 (s, 3H), 3.20–2.91 
(m, 2H); 13C NMR (101 MHz, CDCl3) δ 171.8, 171.2, 165.5, 141.0, 136.4, 135.8, 130.4, 126.4, 94.4, 53.1, 52.3, 49.2, 
36.1; ESI-HRMS calcd for C13H14INNaO5 (M + Na)+ 413.9809, found 413.9801; [α]20D − 22.0° (c 0.2, MeOH).
6 was synthesised from 6e (27 mg, 0.07 mmol) according to the general ester hydrolysis procedure to give 
24 mg (97%) of a white solid: tR = 8.93 min (HPLC); 1H NMR (400 MHz, Acetone-d6) δ 8.25 (t, J = 1.7 Hz, 1H), 
8.13–8.07 (m, 1H), 7.94–7.89 (m, 2H), 7.30 (t, J = 7.8 Hz, 1H), 5.06–4.99 (m, 1H), 3.09–2.93 (m, 2H); 13C NMR 
(101 MHz, Acetone-d6) δ 172.3, 172.2, 165.9, 141.2, 137.3, 137.1, 131.4, 127.6, 94.4, 50.3, 36.4; ESI-HRMS calcd 
for C11H9INO5 (M − H)− 361.9531, found 361.9531; [α]20D + 4.0° (c 0.2, MeOH).
(4-Bromobenzoyl)-L-aspartic acid (7). Dimethyl (4-bromobenzoyl)-L-aspartate (7e) was synthesised 
from 4-bromobenzoic acid (133 mg, 0.66 mmol) and 2 (99 mg, 0.50 mmol) according to the general amide cou-
pling procedure. Purification by flash column chromatography (EtOAc:petroleum ether, 1:1) gave 137 mg (80%) 
of a beige solid: Rf = 0.35 (EtOAc:petroleum ether, 1:1); 1H NMR (400 MHz, CDCl3) δ 7.71–7.66 (m, 2H), 7.61–
7.56 (m, 2H), 7.23–7.17 (m, 1H), 5.07–5.00 (m, 1H), 3.80 (s, 3H), 3.71 (s, 3H), 3.19–2.93 (m, 2H); 13C NMR 
(101 MHz, CDCl3) δ 171.9, 171.2, 166.1, 132.7, 132.0, 128.9, 126.8, 53.1, 52.3, 49.1, 36.1; ESI-HRMS calcd for 
C13H14BrNNaO5 (M + Na)+ 365.9948, found 365.9937; [α]20D −22.5° (c 0.2, MeOH).
7 was synthesised from 7e (25 mg, 0.07 mmol) according to the general ester hydrolysis procedure to give 
21 mg (93%) of a white solid: tR = 8.73 min (HPLC); 1H NMR (400 MHz, Acetone-d6) δ 10.69 (br s, 2H), 8.09–8.01 
(m, 1H), 7.89–7.82 (m, 2H), 7.72–7.65 (m, 2H), 5.07–4.99 (m, 1H), 3.09–2.93 (m, 2H); 13C NMR (101 MHz, 
Acetone-d6) δ 172.4, 172.3, 166.5, 134.3, 132.5, 130.2, 126.5, 50.3, 36.4; ESI-HRMS calcd for C11H9BrNO5 
(M − H)− 313.9670, found 313.9674; [α]20D + 4.0° (c 0.2, MeOH).
(2-(4-Bromophenyl)acetyl)-L-aspartic acid (8). A dry flask under an argon atmosphere was charged with 
4-bromophenylacetic acid (300 mg, 1.4 mmol), 2 (276 mg, 1.4 mmol), DMF (5 mL), N,N-diisopropylethylamine 
(0.85 mL), 1-hydroxybenzotriazole (256 mg, 1.67 mmol), and N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (321 mg, 1.67 mmol). The reaction was stirred overnight at rt. After completion, the solvent was 
evaporated and the residue was extracted with EtOAc (x3). The organic phases were combined, washed with 
aqueous 1 M HCl, saturated aqueous NaHCO3, brine, and dried over Na2SO4 and concentrated in vacuo. The 
residue was purified by flash chromatography (EtOAc:petroleum ether, 1:1) to give 317 mg (63%) of dimethyl 
(2-(4-bromophenyl)acetyl)-L-aspartate (8e) as a white solid: Rf = 0.14 (EtOAc:petroleum ether, 1:1); 1H NMR 
(400 MHz, CDCl3) δ 7.50–7.44 (m, 2H), 7.19–7.13 (m, 2H), 6.47 (d, J = 7.5 Hz, 1H), 4.86–4.79 (m, 1H), 3.74 (s, 
3H), 3.64 (s, 3H), 3.54 (s, 2H), 3.04–2.96 (m, 1H), 2.86–2.78 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 171.3, 170.9, 
170.0, 133.4, 132.0, 131.0, 121.4 52.8, 52.0, 48.7, 42.8, 35.9; ESI-HRMS calcd for C14H17BrNO5 (M + H)+ 358.0285, 
found 358.0295; [α]20D − 6.0° (c 0.2, MeCN).
8 was synthesised from 8e (50 mg, 0.14 mmol) according to the general ester hydrolysis procedure to give 
45 mg (98%) of a white solid: tR = 8.88 min (HPLC); 1H NMR (400 MHz, DMSO-d6) δ 8.44 (d, J = 7.9 Hz, 1H), 
7.54–7.41 (m, 2H), 7.21 (d, J = 8.4 Hz, 2H), 4.55–4.45 (m, 1H), 3.45 (s, 2H), 2.73–2.64 (m, 1H), 2.62–2.53 (m, 1H); 
13C NMR (101 MHz, DMSO-d6) δ 177.5, 176.8, 174.8, 140.9, 136.5, 136.2, 124.7, 54.0, 46.3, 41.3; ESI-HRMS calcd 
for C12H12BrNNaO5 (M + Na)+ 351.9791, found 351.9775; [α]20D + 3.0° (c 0.2, MeOH).
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(2-(4′-Fluoro-[1,1′-biphenyl]-4-yl)acetyl)-L-aspartic acid (9). Dimethyl (2-(4′-fluoro-[1,1′-biph
enyl]−4-yl)acetyl)-L-aspartate (9e) was synthesised from 8e (100 mg, 0.28 mmol) and 4-fluorophenylboronic 
acid (43 mg, 0.31 mmol) according to the general Suzuki coupling procedure. Purification by flash chromatogra-
phy (EtOAc:petroleum ether, 1:4) gave 80 mg (77%) of a white solid: Rf = 0.22 (EtOAc:petroleum ether, 1:1); 1H 
NMR (400 MHz, CDCl3) δ 7.57–7.49 (m, 4H), 7.34 (d, J = 8.4 Hz, 2H), 7.15–7.08 (m, 2H), 6.51 (d, J = 7.6 Hz, 1H), 
4.89–4.82 (m, 1H), 3.73 (s, 3H), 3.65–2.60 (m, 5H), 3.04–2.96 (m, 1H), 2.88–2.80 (m, 1H); 13C NMR (101 MHz, 
CDCl3) δ 171.3, 171.0, 170.5, 160.7 (d, J = 292.3 Hz), 139.3, 136.8 (d, J = 3.3 Hz), 133.5, 129.8, 128.6 (d, J = 8.0 Hz), 
127.5, 115.7 (d, J = 21.5 Hz), 52.8, 52.0, 48.7, 43.1, 36.0; ESI-HRMS calcd for C20H20FNNaO5 (M + Na)+ 396.1218, 
found 396.1224; [α]20D − 5.0° (c 0.2, MeCN).
9 was synthesised from 9e (73 mg, 0.20 mmol) according to the general ester hydrolysis procedure to give 
65 mg (96%) of a white solid: tR = 10.25 min (HPLC); 1H NMR (400 MHz, Acetone-d6) δ 7.71–7.65 (m, 2H), 
7.58–7.54 (m, 2H), 7.42 (d, J = 8.1 Hz, 2H), 7.25–7.18 (m, 2H), 4.85–4.79 (m, 1H), 3.65 (s, 2H), 2.90–2.86 (m, 
2H); 13C NMR (101 MHz, Acetone-d6) δ 176.6, 176.5, 175.6, 167.6 (d, J = 244.4 Hz), 143.4, 142.3 (d, J = 3.2 Hz), 
140.4, 135.0, 133.8 (d, J = 8.1 Hz), 131.9, 120.7 (d, J = 21.6 Hz), 53.9, 47.1, 40.8; ESI-HRMS calcd for C18H15FNO5 
(M + H)+ 344.0940, found 344.0949; [α]20D + 14.6° (c 0.2, MeCN).
(5-Phenylfuran-2-carbonyl)-L-aspartic acid (10). Dimethyl (5-phenylfuran-2-carbonyl)-L-aspartate 
(10e) was synthesised from 4e (100 mg, 0.30 mmol) and phenylboronic acid (40 mg, 0.33 mmol) according to 
the general Suzuki coupling procedure. Purification by flash chromatography (EtOAc:petroleum ether, 1:3) gave 
67 mg (67%) of a clear oil: Rf = 0.25 (EtOAc:petroleum ether, 1:1); 1H NMR (400 MHz, CDCl3) δ 7.76–7.72 (m, 
2H), 7.46–7.33 (m, 4H), 7.22 (d, J = 3.6 Hz, 1H), 6.75 (d, J = 3.6 Hz, 1H), 5.10–5.04 (m, 1H), 3.82 (s, 3H), 3.73 (s, 
3H), 3.20–3.12 (m 1H), 3.03–2.95 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 171.6, 171.1, 158.0, 156.0, 146.3, 129.6, 
128.9, 128.8, 124.6, 117.2, 107.3, 53.0, 52.1, 48.3, 36.3; ESI-HRMS calcd for C17H18NO6 (M + H)+ 332.1129, found 
332.1118; [α]20D − 7.5° (c 0.2, MeCN).
10 was synthesised from 10e (50 mg, 0.15 mmol) according to the general ester hydrolysis procedure to give 
44 mg (96%) of a white solid: tR = 9.38 min (HPLC); 1H NMR (400 MHz, Acetone-d6) δ 8.08 (d, J = 8.1 Hz, 1H), 
7.87–7.80 (m, 2H), 7.49–7.42 (m, 2H), 7.40–7.33 (m, 1H), 7.21 (d, J = 3.6 Hz, 1H), 7.01 (d, J = 3.6 Hz, 1H), 5.09–
5.01 (m, 1H), 3.12–2.97 (m, 2H); 13C NMR (101 MHz, Acetone-d6) δ 172.4, 172.3, 158.5, 156.3, 148.0, 130.7, 129.8, 
129.5, 125.2, 117.1, 108.2, 49.4, 36.5; ESI-HRMS calcd for C15H13NNaO6 (M + Na)+ 326.0635, found 326.0645; 
[α]20D + 3.9° (c 0.2, MeCN).
(5-(o-Tolyl)furan-2-carbonyl)-L-aspartic acid (11). Dimethyl (5-(o-tolyl)furan-2-carbonyl)-L-aspartate 
(11e) was synthesised from 4e (100 mg, 0.30 mmol) and o-tolylboronic acid (45 mg, 0.33 mmol) according to 
the general Suzuki coupling procedure. Purification by flash chromatography (EtOAc:petroleum ether, 1:3) gave 
80 mg (77%) of a clear oil: Rf = 0.29 (EtOAc:petroleum ether, 1:1); 1H NMR (400 MHz, CDCl3) δ 7.71–7.76 (m, 
1H), 7.39 (d, J = 8.1 Hz, 1H), 7.32–7.27 (m, 3H), 7.25 (d, J = 3.6 Hz, 1H), 6.64 (d, J = 3.6 Hz), 5.09–5.03 (m, 1H), 
3.80 (s, 3H), 3.71 (s, 3H), 3.19–3.11 (m, 1H), 3.02–3.94 (m, 1H), 2.54 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 
171.5, 171.1, 158.0, 155.8, 146.0, 135.4, 131.4, 129.0, 128.8, 127.8, 126.2, 116.6, 110.6, 52.9, 52.1, 48.2, 36.3, 21.7; 
ESI-HRMS calcd for C18H19NNaO6 (M + Na)+ 368.1105, found 368.1120; [α]20D + 23.7° (c 0.2, DCM).
11 was synthesised from 11e (50 mg, 0.14 mmol) according to the general ester hydrolysis procedure to give 
45 mg (98%) of a pale yellow solid: tR = 9.85 min (HPLC); 1H NMR (400 MHz, Acetone-d6) δ 7.99 (d, J = 8.3 Hz, 
1H), 7.77–7.73 (m, 1H), 7.34–7.26 (m, 3H), 7.23 (d, J = 3.6 Hz, 1H), 6.83 (d, J = 3.6 Hz, 1H), 5.08–5.01 (m, 
1H), 3.05 (d, J = 5.7 Hz, 2H), 2.52 (s, 3H); 13C NMR (101 MHz, Acetone-d6) δ 172.5, 172.3, 158.5, 156.1, 147.7, 
136.2, 132.2, 130.0, 129.5, 128.4, 127.1, 116.7, 111.6, 49.2, 36.4, 21.9; ESI-HRMS calcd for C16H14NO6 (M + H)+ 
316.0827, found 316.0816; [α]20D + 30.5° (c 0.2, MeCN).
(5-(m-Tolyl)furan-2-carbonyl)-L-aspartic acid (12). Dimethyl (5-(m-tolyl)furan-2-carbonyl)- 
L-aspartate (12e) was synthesised from 4e (100 mg, 0.30 mmol) and m-tolylboronic acid (45 mg, 0.33 mmol) 
according to the general Suzuki coupling procedure. Purification by flash chromatography (EtOAc:petroleum 
ether, 1:3) gave 70 mg (68%) of a clear oil: Rf = 0.23 (EtOAc:petroleum ether, 1:1); 1H NMR (400 MHz, CDCl3) δ 
7.56–7.52 (m, 2H), 7.37 (d, J = 8.1Hz, 1H), 7.32 (t, J = 7.9 Hz, 1H), 7.22 (d, J = 3.6 Hz, 1H), 7.17 (d, J = 7.6 Hz, 1H), 
6.73 (d, J = 3.6 Hz, 1H), 5.11–5.04 (m, 1H), 3.82 (s, 3H), 3.73 (s, 3H), 3.20–3.12 (m, 1H), 3.04–2.96 (m, 1H), 2.42 
(s, 3H); 13C NMR (101 MHz, CDCl3) δ 171.6, 171.1, 158.0, 156.2, 146.2, 138.6, 129.7, 129.5, 128.8, 125.2, 121.9, 
117.2, 107.2, 53.0, 52.1, 48.3, 36.3, 21.5; ESI-HRMS calcd for C18H19NaNO6 (M + Na)+ 368.1105, found 368.1103; 
[α]20D + 19.3° (c 0.2, MeCN).
12 was synthesised from 12e (50 mg, 0.14 mmol) according to the general ester hydrolysis procedure to give 
46 mg (quant.) of a white solid: tR = 9.88 min (HPLC); 1H NMR (400 MHz, Acetone-d6) δ 8.04 (d, J = 8.1 Hz, 1H), 
7.68–7.61 (m, 2H), 7.34 (t, J = 7.7 Hz, 1H), 7.22–7.17 (m, 2H), 6.99 (d, J = 3.6 Hz, 1H), 5.08–5.00 (m, 1H), 3.10–
2.96 (m, 2H), 2.37 (s, 3H); 13C NMR (101 MHz, Acetone-d6) δ 172.34, 172.27, 156.5, 154.2, 148.0, 139.4, 130.7, 
130.3, 129.7, 125.8, 122.5, 117.0, 108.1, 49.4, 36.43, 21.4; ESI-HRMS calcd for C16H14NO6 (M + H)+ 316.0827, 
found 316.0826; [α]20D + 7.0° (c 0.2, MeCN).
(5-(p-Tolyl)furan-2-carbonyl)-L-aspartic acid (13). Dimethyl (5-(p-tolyl)furan-2-carbonyl)-L-aspartate 
(13e) was synthesised from 4e (100 mg, 0.30 mmol) and p-tolylboronic acid (45 mg, 0.33 mmol) according to 
the general Suzuki coupling procedure. Purification by flash chromatography (EtOAc:petroleum ether, 1:3) gave 
80 mg (77%) of a clear oil: Rf = 0.26 (EtOAc:petroleum ether, 1:1); 1H NMR (400 MHz, CDCl3) δ 7.66–7.59 (m, 
2H), 7.37 (d, J = 8.1 Hz, 1H), 7.23 (d, J = 7.9 Hz, 2H), 7.21 (d, J = 3.6 Hz, 1H), 6.69 (d, J = 3.6 Hz, 1H), 5.10–5.03 
(m, 1H), 3.81 (s, 3H), 3.71 (s, 3H), 3.19–3.11 (m, 1H), 3.03–2.95 (m, 1H), 2.39 (s, 3H); 13C NMR (101 MHz, 
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CDCl3) δ 171.6, 171.1, 158.0, 156.2, 145.9, 138.9, 129.6, 126.9, 124.6, 117.2, 106.6, 52.9, 52.1, 48.3, 36.3, 21.4; 
ESI-HRMS calcd for C18H19NaNO6 (M + Na)+ 368.1105, found 368.1104; [α]20D + 15.5° (c 0.2, DCM).
13 was synthesised from 13e (50 mg, 0.14 mmol) according to the general ester hydrolysis procedure to give 
45 mg (98%) of a white solid: tR = 9.89 min (HPLC); 1H NMR (400 MHz, Acetone-d6) δ 7.74–7.69 (m, 2H), 7.27 (d, 
J = 8.0 Hz, 2H), 7.18 (d, J = 3.6 Hz, 1H), 6.94 (d, J = 3.6 Hz, 1H), 5.03 (t, J = 5.9 Hz, 1H), 3.11–2.96 (m, 2H), 2.35 
(s, 3H); 13C NMR (101 MHz, Acetone-d6) δ 172.48, 172.45, 158.5, 156.6, 147.7, 139.6, 130.4, 128.0, 125.3, 117.2, 
107.5, 49.3, 36.6, 21.3; ESI-HRMS calcd for C14H16NO6 (M + H)+ 316.0827, found 316.0821; [α]20D + 10.5° (c 0.2, 
MeCN).
(5-(3-(Hydroxymethyl)phenyl)furan-2-carbonyl)-L-aspartic acid (14). Dimethyl (5-(3-(hydrox-
ymethyl)phenyl)furan-2-carbonyl)-L-aspartate (14e) was synthesised from 4e (107 mg, 0.32 mmol) and 
3-hydroxymethylphenylboronic acid (54 mg, 0.35 mmol) according to the general Suzuki coupling procedure. 
Purification by flash chromatography (EtOAc:petroleum ether, 2:1) gave 55 mg (47%) of a clear oil: Rf = 0.29 
(EtOAc:petroleum ether, 2:1); 1H NMR (400 MHz, CDCl3) δ 7.73 (s, 1H), 7.66 (d, J = 7.7 Hz, 1H), 7.46–7.33 
(m, 3H), 7.21 (d, J = 3.6 Hz, 1H), 6.76 (d, J = 3.6 Hz, 1H), 5.09–5.03 (m, 1H), 4.76 (s, 2H), 3.81 (s, 3H), 3.73 (s, 
3H), 3.19–3.11 (m, 1H), 3.03–2.95 (m, 1H), 1.99 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 171.6, 171.1, 157.9, 
155.8, 146.3, 141.7, 129.8, 129.1, 127.3, 123.8, 123.0, 117.2, 107.5, 65.0, 52.9, 52.1, 48.3, 36.2; ESI-HRMS calcd for 
C18H20NO7 (M + H)+ 362.1234, found 362.1246; [α]20D − 8.0° (c 0.2, MeCN).
14 was synthesised from 14e (50 mg, 0.14 mmol) according to the general ester hydrolysis procedure to give 
44 mg (95%) of a white solid: tR = 8.04 min (HPLC); 1H NMR (400 MHz, Acetone-d6) δ 8.11 (d, J = 8.3 Hz, 1H), 
7.82 (s, 1H), 7.70 (d, J = 7.5 Hz, 1H), 7.45–7.33 (m, 2H), 7.21 (d, J = 3.6 Hz, 1H), 7.00 (d, J = 3.6 Hz, 1H), 5.09–5.01 
(m, 1H), 4.68 (s, 2H), 3.10–2.97 (m, 2H), 1.31–1.25 (m, 1H); 13C NMR (101 MHz, Acetone-d6) δ 172.5, 172.4, 
158.6, 156.6, 147.9, 144.2, 130.6, 129.7, 127.8, 123.8, 123.4, 117.2, 108.2, 64.5, 49.4, 36.5; ESI-HRMS calcd for 
C16H14NO7 (M + H)+ 332.0776, found 332.0760; [α]20D + 14.5° (c 0.2, MeCN).
(5-(4-Hydroxyphenyl)furan-2-carbonyl)-L-aspartic acid (15). Dimethyl (5-(4-hydroxyphenyl)
furan-2-carbonyl)-L-aspartate (15e) was synthesised from 4e (100 mg, 0.30 mmol) and 4-hydroxyphenylboronic 
acid (45 mg, 0.33 mmol) according to the general Suzuki coupling procedure. Purification by flash chromatog-
raphy (EtOAc:petroleum ether, 1:2) gave 30 mg (29%) of a clear oil: Rf = 0.23 (EtOAc:petroleum ether, 1:1); 1H 
NMR (400 MHz, CDCl3) δ 7.64–7.56 (m, 2H), 7.37 (d, J = 8.1 Hz, 1H), 7.21 (d, J = 3.6 Hz, 1H), 6.94–6.87 (m, 2H), 
6.59 (d, J = 3.6 Hz, 1H), 5.79 (s, 1H), 5.10–5.04 (m, 1H), 3.82 (s, 3H), 3.73 (s, 3H), 3.20–3.12 (m, 1H), 3.03–2.95 
(m, 1H); 13C NMR (101 MHz, CDCl3) δ 171.7, 171.2, 158.2, 156.6, 156.3, 145.5, 126.4, 122.5, 117.5, 115.9, 105.8, 
53.0, 52.1, 48.3, 36.3; ESI-HRMS calcd for C17H18NO7 (M + H)+ 348.1078, found 348.1083; [α]20D − 3.5° (c 0.2, 
MeCN).
15 was synthesised from 15e (27 mg, 0.08 mmol) according to the general ester hydrolysis procedure to give 
24 mg (97%) of a pale brown solid: tR = 8.15 min (HPLC); 1H NMR (400 MHz, Acetone-d6) δ 7.99 (d, J = 8.2 Hz, 
1H), 7.71–7.64 (m, 2H), 7.16 (d, J = 3.6 Hz, 1H), 6.94–6.88 (m, 2H), 6.80 (d, J = 3.6 Hz, 1H), 5.07–4.99 (m, 1H), 
3.09–2.97 (m, 2H); 13C NMR (101 MHz, Acetone-d6) δ 172.41, 172.36, 159.0, 158.6, 156.9, 147.1, 127.0, 122.5, 
117.2, 116.7, 106.1, 49.3, 36.5; ESI-HRMS calcd for C15H12NO7 (M + H)+ 318.0619, found 318.0615; [α]20D + 
5.4° (c 0.2, MeCN).
(5-(2-Methoxyphenyl)furan-2-carbonyl)-L-aspartic acid (16). Dimethyl (5-(2-methoxyphenyl)
furan-2-carbonyl)-L-aspartate (16e) was synthesised from 4e (100 mg, 0.30 mmol) and o-methoxyphenylboronic 
acid (40 mg, 0.33 mmol) according to the general Suzuki coupling procedure. Purification by flash chromatog-
raphy (EtOAc:petroleum ether, 1:3) gave 61 mg (56%) of a clear oil: Rf = 0.26 (EtOAc:petroleum ether, 1:1); 1H 
NMR (400 MHz, CDCl3) δ 7.89 (dd, J = 7.8, 1.7 Hz, 1H), 7.39 (d, J = 8.1 Hz, 1H), 7.33 (ddd, J = 8.4, 7.4, 1.7 Hz, 
1H), 7.23 (d, J = 3.6 Hz, 1H), 7.07 (td, J = 7.7, 1.0 Hz, 1H), 7.03 (d, J = 3.6 Hz, 1H), 6.99 (d, J = 8.3 Hz, 1H), 5.12–
5.01 (m, 1H), 3.96 (s, 3H), 3.81 (s, 3H), 3.73 (s, 3H), 3.20–3.12 (m, 1H), 3.03–2.95 (m, 1H); 13C NMR (101 MHz, 
CDCl3) δ 171.6, 171.2, 158.1, 156.3, 152.5, 145.2, 129.6, 126.6, 120.9, 118.6, 117.2, 112.1, 111.2, 55.5, 52.9, 52.1, 
48.3, 36.3; ESI-HRMS calcd for C18H20NO7 (M + H)+ 362.1234, found 362.1249; [α]20D − 5.9° (c 0.2, MeCN).
16 was synthesised from 16e (49 mg, 0.13 mmol) according to the general ester hydrolysis procedure to give 
40 mg (89%) of a white solid: tR = 9.59 min (HPLC); 1H NMR (400 MHz, Acetone-d6) δ 8.07 (d, J = 8.3 Hz, 1H), 
7.93 (dd, J = 7.8, 1.7 Hz, 1H), 7.35 (ddd, J = 8.4, 7.4, 1.7 Hz, 1H), 7.19 (d, J = 3.6 Hz, 1H), 7.14 (d, J = 8.4, 0.8 Hz, 
1H), 7.08 (d, J = 3.6 Hz, 1H), 7.04 (td, J = 7.7, 1.1 Hz, 1H), 5.08–5.02 (m, 1H), 3.99 (s, 3H), 3.10–2.98 (m, 2H); 13C 
NMR (101 MHz, Acetone-d6) δ 172.5, 172.4, 158.6, 157.3, 152.9, 146.9, 130.5, 127.0, 121.5, 119.4, 117.1, 112.8, 
112.5, 55.9, 49.4, 36.5; ESI-HRMS calcd for C16H15NNaO7 (M + Na)+ 356.0741, found 356.0743; [α]20D + 3.0° (c 
0.2, MeCN).
(5-(4-Methoxyphenyl)furan-2-carbonyl)-L-aspartic acid (17). Dimethyl (5-(4-methoxyphenyl)
furan-2-carbonyl)-L-aspartate (17e) was synthesised from 4e (100 mg, 0.30 mmol) and p-methoxyphenylboronic 
acid (40 mg, 0.33 mmol) according to the general Suzuki coupling procedure. Purification by flash chromatog-
raphy (EtOAc:petroleum ether, 1:3) gave 89 mg (82%) of a clear oil: Rf = 0.20 (EtOAc:petroleum ether, 1:1); 1H 
NMR (400 MHz, CDCl3) δ 7.69–7.64 (m, 2H), 7.35 (d, J = 8.0 Hz, 1H), 7.20 (d, J = 3.60 Hz, 1H), 6.99–6.92 (m, 
2H), 6.61 (d, J = 3.6 Hz, 1H), 5.09–5.03 (m, 1H), 3.86 (s, 3H), 3.81 (s, 3H), 3.71 (s, 3H), 3.19–3.11 (m, 1H), 
3.02–2.94 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 171.6, 171.2, 160.2, 158.0, 156.1, 145.7, 126.2, 122.5, 117.3, 
114.4, 105.8, 55.4, 52.9, 52.1, 48.2, 36.3; ESI-HRMS calcd for C18H20NO7 (M + H)+ 362.1234, found 362.1249, 
[α]20D − 6.0° (c 0.2, MeCN).
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17 was synthesised from 17e (75 mg, 0.21 mmol) according to the general ester hydrolysis procedure to give 
66 mg (96%) of a white solid: tR = 9.48 min (HPLC); 1H NMR (400 MHz, Acetone-d6) δ 8.05 (d, J = 8.2 Hz, 1H), 
7.75 (d, J = 8.8 Hz, 2H), 7.19 (d, J = 3.6 Hz, 1H), 7.00 (d, J = 8.8 Hz, 2H), 6.84 (d, J = 3.6 Hz, 1H), 5.09–5.00 (m, 
1H), 3.83 (s, 3H), 3.11–2.98 (m, 2H); 13C NMR (101 MHz, Acetone-d6) δ 172.5, 172.4, 161.2, 158.7, 156.7, 147.3, 
126.9, 123.5, 117.4, 115.3, 106.6, 55.8, 49.4, 36.5; ESI-HRMS calcd for C16H15NNaO7 (M + Na)+ 356.0741, found 
356.0755; [α]20D + 2.5° (c 0.2, MeCN).
(5-(4-(Trifluoromethyl)phenyl)furan-2-carbonyl)-L-aspartic acid (18). Dimethyl (5-(4-(trif-
luoromethyl)phenyl)furan-2-carbonyl)-L-aspartate (18e) was synthesised from 4e (100 mg, 0.30 mmol) and 
4-trifluoromethylphenylboronic acid (63 mg, 0.33 mmol) according to the general Suzuki coupling procedure. 
Purification by flash chromatography (EtOAc:petroleum ether, 1:3) gave 67 mg (56%) of a clear oil: Rf = 0.59 
(EtOAc:petroleum ether, 2:1); 1H NMR (400 MHz, CDCl3) δ 7.83 (d, J = 8.6 Hz, 2H), 7.68 (d, J = 8.6 Hz, 2H), 7.44 
(d, J = 8.1 Hz, 1H), 7.25 (d, J = 3.6 Hz, 1H), 6.86 (d, J = 3.6 Hz, 1H), 5.09–5.03 (m, 1H), 3.82 (s, 3H), 3.74 (s, 3H), 
3.21–3.13 (m, 1H), 3.03–2.95 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 171.6, 171.0, 157.7, 154.2, 147.2, 132.7, 
130.5 (q, J = 32.7 Hz), 126.0 (q, J = 3.8 Hz), 125.3, 124.7, 117.1, 109.1, 53.0, 52.2, 48.3, 36.2; ESI-HRMS calcd for 
C18H16F3NaNO6 (M + Na)+ 422.0822, found 422.0832; [α]20D − 5.0° (c 0.2, MeCN).
18 was synthesised from 18e (50 mg, 0.13 mmol) according to the general ester hydrolysis procedure to give 
46 mg (99%) of a white solid: tR = 10.73 min (HPLC); 1H NMR (400 MHz, Acetone-d6) δ 8.19 (d, J = 8.2 Hz, 1H), 
8.02 (t, J = 9.7 Hz, 2H), 7.78 (d, J = 8.3 Hz, 2H), 7.26 (d, J = 3.6 Hz, 1H), 7.21 (d, J = 3.6 Hz, 1H), 5.10–5.01 (m, 
1H), 3.08–3.00 (m, 2H); 13C NMR (101 MHz, Acetone-d6) δ 172.4, 172.3, 158.4, 154.6, 148.9, 134.2, 130.4 (q, 
J = 32.3 Hz), 126.8 (q, J = 3.8 Hz), 125.7, 117.2, 110.5, 49.5, 36.5; ESI-HRMS calcd for C16H11F3NO6 (M + H)+ 
370.0544, found 370.0528; [α]20D + 3.5° (c 0.2, MeCN).
(5-(4-Cyanophenyl)furan-2-carbonyl)-L-aspartic acid (19). Dimethyl (5-(4-cyanophenyl)
furan-2-carbonyl)-L-aspartate (19e) was synthesised from 4e (100 mg, 0.30 mmol) and 4-cyanophenylboronic 
acid (48 mg, 0.33 mmol) according to the general Suzuki coupling procedure. Purification by flash chromatog-
raphy (EtOAc:petroleum ether, 1:3) gave 70 mg (66%) of a clear oil: Rf = 0.21 (EtOAc:petroleum ether, 1:1); 1H 
NMR (400 MHz, CDCl3) δ 7.85–7.79 (m, 2H), 7.75–7.69 (m, 2H), 7.44 (d, J = 8.0 Hz, 1H), 7.25 (d, J = 3.7 Hz, 1H), 
6.90 (d, J = 3.7 Hz, 1H), 5.08–5.02 (m, 1H), 3.82 (s, 3H), 3.74 (s, 3H), 3.21–3.13 (m, 1H), 3.03–2.95 (m, 1H); 13C 
NMR (101 MHz, CDCl3) δ 171.6, 170.9, 157.5, 153.6, 147.6, 133.3, 132.8, 124.9, 118.5, 117.1, 112.0, 110.0, 53.0, 
52.2, 48.3, 36.1; ESI-HRMS calcd for C18H16N2NaO6 (M + Na)+ 379.0901, found 379.0892; [α]D20 – 9.5° (c 0.2, 
MeCN).
19 was synthesised from 19e (57 mg, 0.16 mmol) according to the general ester hydrolysis procedure to give 
50 mg (95%) of a pale yellow solid: tR = 9.16 min (HPLC); 1H NMR (400 MHz, Acetone-d6) δ 8.18 (d, J = 8.2 Hz, 
1H), 8.06–8.12 (m, 2H), 7.89–7.85 (m, 2H), 7.27 (d, J = 3.6 Hz, 1H), 7.25 (d, J = 3.6 Hz, 1H), 5.06–5.00 (m, 1H), 
3.07–2.98 (m, 2H); 13C NMR (101 MHz, Acetone-d6) δ 172.3, 172.2, 158.2, 154.2, 145.9, 134.5, 133.7, 125.7, 119.1, 
117.2, 112.4, 111.2, 49.5, 36.4; ESI-HRMS calcd for C16H11N2O6 (M + H)+ 327.0623, found 327.0628; [α]D20 + 
15.8° (c 0.2, MeCN).
(5-(4-(Trifluoromethoxy)phenyl)furan-2-carbonyl)-L-aspartic acid (20). Dimethyl (5-(4-(trif-
luoromethoxy)phenyl)furan-2-carbonyl)-L-aspartate (20e) was synthesised from 4e (100 mg, 0.30 mmol) and 
4-trifluoromethoxyphenylboronic acid (68 mg, 0.33 mmol) according to the general Suzuki coupling procedure. 
Purification by flash chromatography (EtOAc:petroleum ether, 1:3) gave 54 mg (43%) of a clear oil: Rf = 0.32 
(EtOAc:petroleum ether, 1:1); 1H NMR (400 MHz, CDCl3) δ 7.78–7.73 (m, 2H), 7.40 (d, J = 8.0 Hz, 1H), 7.28 
(d, J = 8.5 Hz, 2H), 7.23 (d, J = 3.4 Hz, 1H), 6.75 (d, J = 3.6 Hz, 1H), 5.09–5.03 (m, 1H), 3.82 (s, 3H), 3.73 (s, 3H), 
3.20–3.12 (m, 1H), 3.02–2.94 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 171.6, 171.1, 157.8, 154.6, 149.4, 146.7, 
135.5, 128.3, 126.1, 121.4, 117.2, 107.9, 53.0, 52.1, 48.3, 36.2; ESI-HRMS calcd for C18H16F3NNaO7 (M + Na)+ 
438.0771, found 438.0782; [α]20D − 8.0° (c 0.2, MeCN).
20 was synthesised from 20e (46 mg, 0.11 mmol) according to the general ester hydrolysis procedure to give 
41 mg (95%) of a white solid: tR = 10.88 min (HPLC); 1H NMR (400 MHz, Acetone-d6) δ 8.00–7.92 (m, 2H), 
7.46–7.38 (m, 2H), 7.22 (d, J = 3.6 Hz, 1H), 7.08 (d, J = 3.6 Hz, 1H), 5.03 (t, J = 5.9 Hz, 1H), 3.07–2.99 (m, 2H); 
13C NMR (101 MHz, Acetone-d6) δ 172.39, 172.36, 158.4, 154.8, 149.8, 148.5, 129.9, 127.1, 122.4, 117.2, 109.1, 
49.4, 36.5; ESI-HRMS calcd for C16H11F3NO7 (M + H)+ 386.0493, found 386.050; [α]20D + 6.5° (c 0.2, MeCN).
(5-(4-Ethoxyphenyl)furan-2-carbonyl)-L-aspartic acid (21). Dimethyl (5-(4-ethoxyphenyl)
furan-2-carbonyl)-L-aspartate (21e) was synthesised from 15e (61 mg, 0.18 mmol) and ethyl iodide (50 µL, 
0.62 mmol) according to the general alkylation procedure. After one day of stirring, additional ethyl iodide (50 µL, 
0.62 mmol) was added. Purification by flash column chromatography (EtOAc:petroleum ether, 1:1) gave 55 mg 
(95%) of a pale yellow solid: Rf = 0.22 (EtOAc:petroleum ether, 1:1); 1H NMR (400 MHz, Acetone-d6) δ 8.09–8.02 
(m, 1H), 7.78–7.73 (m, 2H), 7.16 (d, J = 3.6 Hz, 1H), 7.03–6.98 (m, 2H), 6.85 (d, J = 3.6 Hz, 1H), 5.07–4.99 (m, 
1H), 4.10 (q, J = 7.0 Hz, 2H), 3.71 (s, 3H), 3.67 (s, 3H), 3.09–2.91 (m, 3H), 1.38 (t, J = 7.0 Hz, 3H); 13C NMR 
(101 MHz, Acetone-d6) δ 172.0, 171.7, 160.6, 158.4, 156.7, 147.3, 126.9, 123.4, 117.3, 115.8, 106.5, 64.3, 52.8, 52.1, 
49.6, 36.7, 15.0; ESI-HRMS calcd for C19H21NNaO7 (M + Na)+ 398.1210, found 398.1223; [α]20D − 4.5° (c 0.2, 
MeOH).
21 was synthesised from 21e (44 mg, 0.12 mmol) according to the general ester hydrolysis procedure to give 
37 mg (89%) of a pale yellow foam: tR = 10.01 min (HPLC); 1H NMR (400 MHz, Acetone-d6) δ 10.93 (br s, 2H), 
8.05–7.97 (m, 1H), 7.80–7.71 (m, 2H), 7.16 (d, J = 3.6 Hz, 1H), 7.04–6.97 (m, 2H), 6.85 (d, J = 3.6 Hz, 1H), 5.08–
5.00 (m, 1H), 4.10 (q, J = 7.0 Hz, 2H), 3.12–2.96 (m, 2H), 1.38 (t, J = 7.0 Hz, 3H); 13C NMR (101 MHz, Acetone-d6) 
www.nature.com/scientificreports/
13SCiENtiFiC REPORTS |  (2018) 8:10010  | DOI:10.1038/s41598-018-28263-7
δ 172.42, 172.38, 160.6, 158.6, 156.6, 147.4, 126.9, 123.4, 117.2, 115.8, 106.5, 64.3, 49.4, 36.5, 15.1; ESI-HRMS 
calcd for C17H16NO7 (M − H)− 346.0932, found 346.0945; [α]20D + 6.5° (c 0.2, MeOH).
(5-(4-Isopropoxyphenyl)furan-2-carbonyl)-L-aspartic acid (22). Dimethyl (5-(4-isopropoxyphenyl)
furan-2-carbonyl)-L-aspartate (22e) was synthesised from 15e (60 mg, 0.17 mmol) and 2-bromopropane 
(50 µL, 0.53 mmol) according to the general alkylation procedure. In addition, KI (6 mg, 0.03 mmol) was added 
to promote the reaction. After one day of stirring, additional 2-bromopropane (50 µL, 0.53 mmol) was added. 
Purification by flash column chromatography (EtOAc:petroleum ether, 1:1) gave 11 mg (16%) of a pale yellow 
solid: Rf = 0.25 (EtOAc:petroleum ether, 1:1); 1H NMR (400 MHz, Acetone-d6) δ 8.08–8.00 (m, 1H), 7.77–7.71 (m, 
2H), 7.16 (d, J = 3.6 Hz, 1H), 7.03–6.96 (m, 2H), 6.85 (d, J = 3.6 Hz, 1H), 5.08–4.98 (m, 1H), 4.74–4.64 (m, 1H), 
3.71 (s, 3H), 3.67 (s, 3H), 3.09–2.91 (m, 2H), 1.32 (d, J = 6.0 Hz, 6H); 13C NMR (101 MHz, Acetone-d6) δ 172.0, 
171.7, 159.5, 158.5, 156.7, 147.2, 126.9, 123.2, 117.3, 116.9, 106.5, 70.6, 52.8, 52.1, 49.6, 36.7, 22.3; ESI-HRMS 
calcd for C20H23NNaO7 (M + Na)+ 412.1367, found 412.1387.
22 was synthesised from 22e (11 mg, 0.03 mmol) according to the general ester hydrolysis procedure to give 
9 mg (86%) of a pale yellow solid: tR = 10.50 min (HPLC); 1H NMR (400 MHz, Acetone-d6) δ 11.19 (br s, 2H), 
8.02–7.97 (m, 1H), 7.78–7.71 (m, 2H), 7.16 (d, J = 3.6 Hz, 1H), 7.03–6.96 (m, 2H), 6.85 (d, J = 3.6 Hz, 1H), 5.09–
4.98 (m, 1H), 4.74–4.63 (m, 1H), 3.10–2.95 (m, 2H), 1.32 (d, J = 6.0 Hz, 6H); 13C NMR (101 MHz, Acetone-d6) δ 
172.41, 172.38, 159.5, 158.6, 156.7, 147.4, 126.9, 123.3, 117.2, 116.9, 106.5, 70.6, 49.4, 36.5, 22.3; ESI-HRMS calcd 
for C18H18NO7 (M − H)− 360.1089, found 360.1103; [α]20D + 57.0° (c 0.2, MeOH).
(5-(4-((3-Methyloxetan-3-yl)methoxy)phenyl)furan-2-carbonyl)-L-aspartic acid (23). Dimethyl 
(5-(4-((3-methyloxetan-3-yl)methoxy)phenyl)furan-2-carbonyl)-L-aspartate (23e) was synthesised from 15e 
(55 mg, 0.35 mmol) and (3-methyloxetan-3-yl)methyl 4-methylbenzenesulfonate (89 mg, 0.53 mmol) accord-
ing to the general alkylation procedure. In addition, KI (10 mg, 0.06 mmol) was added to promote the reaction. 
Purification by flash column chromatography (EtOAc:petroleum ether, 1:1) gave 38 mg (55%) of a yellow solid: 
Rf = 0.17 (EtOAc:petroleum ether, 1:1); 1H NMR (400 MHz, Acetone-d6) δ 8.10–8.03 (m, 1H), 7.82–7.75 (m, 
2H), 7.17 (d, J = 3.6 Hz, 1H), 7.12–7.06 (m, 2H), 6.88 (d, J = 3.6 Hz, 1H), 5.09–4.98 (m, 1H), 4.55 (d, J = 5.8 Hz, 
2H), 4.35 (d, J = 5.8 Hz, 2H), 4.16 (s, 2H), 3.71 (s, 3H), 3.67 (s, 3H), 3.09–2.89 (m, 2H), 1.43 (s, 3H); 13C NMR 
(101 MHz, Acetone-d6) δ 171.9, 171.7, 160.8, 158.4, 156.6, 147.4, 126.9, 123.8, 117.3, 116.0, 106.7, 79.7, 73.9, 52.8, 
52.1, 49.6, 40.4, 36.7, 21.5; ESI-HRMS calcd for C22H26NO8 (M + H)+ 432.1653, found 432.1668; [α]20D + 0.5° (c 
0.2, MeOH).
23 was synthesised from 23e (30 mg, 0.07 mmol) according to the general ester hydrolysis procedure to give 
26 mg (92%) of a pale yellow foam: tR = 9.55 min (HPLC); 1H NMR (400 MHz, Acetone-d6) δ 10.93 (br s, 2H), 
8.06–7.98 (m, 1H), 7.83–7.75 (m, 2H), 7.17 (d, J = 3.6 Hz, 1H), 7.13–7.05 (m, 2H), 6.88 (d, J = 3.6 Hz, 1H), 5.07–
5.00 (m, 1H), 4.56 (d, J = 5.8 Hz, 2H), 4.35 (d, J = 5.8 Hz, 2H), 4.15 (s, 2H), 3.12–2.97 (m, 2H), 1.43 (s, 3H); 13C 
NMR (101 MHz, Acetone-d6) δ 172.41, 172.38, 160.8, 158.6, 156.5, 147.5, 126.9, 123.8, 117.2, 116.0, 106.7, 79.7, 
73.8, 49.4, 40.4, 36.5, 21.5; ESI-HRMS calcd for C20H20NO8 (M − H)− 402.1194, found 402.1197; [α]20D + 10.0° 
(c 0.2, MeOH).
(5-(4-(3-(Methylsulfonyl)propoxy)phenyl)furan-2-carbonyl)-L-aspartic acid (24). Dimethyl 
(5-(4-(3-(methylsulfonyl)propoxy)phenyl)furan-2-carbonyl)-L-aspartate (24e) was synthesised from 15e (40 mg, 
0.12 mmol) and 3-(methylsulfonyl)propyl 4-methylbenzenesulfonate (69 mg, 0.24 mmol) according to the gen-
eral alkylation procedure. In addition, KI (16 mg, 0.09 mmol) was added to promote the reaction. Purification 
by flash column chromatography (EtOAc:petroleum ether, 2:1) gave 35 mg (65%) of a white solid: Rf = 0.11 
(EtOAc:petroleum ether, 2:1); 1H NMR (400 MHz, Acetone-d6) δ 8.09–8.01 (m, 1H), 7.80–7.74 (m, 2H), 7.16 (d, 
J = 3.6 Hz, 1H), 7.08–7.02 (m, 2H), 6.87 (d, J = 3.6 Hz, 1H), 5.07–4.99 (m, 1H), 4.23 (t, J = 6.1 Hz, 2H), 3.71 (s, 
3H), 3.67 (s, 3H), 3.35–3.27 (m, 2H), 3.07–2.92 (m, 2H), 2.99 (s, 3H), 2.35–2.25 (m, 2H); 13C NMR (101 MHz, 
Acetone-d6) δ 171.9, 171.7, 160.2, 158.4, 156.5, 147.4, 126.9, 123.8, 117.3, 115.9, 106.7, 66.9, 52.8, 52.1, 51.9, 
49.6, 40.8, 36.7, 23.5; ESI-HRMS calcd for C21H26NO9S (M + H)+ 468.1323, found 468.1339; [α]20D − 9.0° (c 0.2, 
MeOH).
24 was synthesised from 24e (25 mg, 0.05 mmol) according to the general ester hydrolysis procedure to give 
24 mg (99%) of a white solid: tR = 8.76 min (HPLC); 1H NMR (400 MHz, DMSO-d6) δ 12.66 (br s, 2H), 8.72–8.64 
(m, 1H), 7.90–7.81 (m, 2H), 7.18 (d, J = 3.6 Hz, 1H), 7.05 (d, J = 8.9 Hz, 2H), 6.96 (d, J = 3.6 Hz, 1H), 4.82–4.73 
(m, 1 H), 4.15 (t, J = 6.2 Hz, 2H), 3.38–3.25 (m, 2H), 3.03 (s, 3H), 2.94–2.68 (m, 2H), 2.24–2.11 (m, 2H); 13C NMR 
(101 MHz, DMSO-d6) δ 172.3, 171.8, 158.6, 157.4, 154.8, 145.9 126.0, 122.3, 116.3, 114.9, 106.0, 65.8, 50.5, 48.5, 
40.2, 35.8, 21.9; ESI-HRMS calcd for C19H20NO9S (M − H)− 438.0864, found 438.0871; [α]20D + 15.0° (c 0.2, 
MeOH).
(4′-Fluoro-[1,1′-biphenyl]-3-carbonyl)-L-aspartic acid (25). Dimethyl (4′-fluoro-[1,1′-biphenyl]-3-c
arbonyl)-L-aspartate (25e) was synthesised from (4-fluorophenyl)boronic acid (36 mg, 0.26 mmol) and 6e (79 mg, 
0.20 mmol) according to the general Suzuki coupling procedure. Purification by flash column chromatography 
(EtOAc:petroleum ether, 1:1) gave 25 mg (35%) of a pale yellow sticky oil: Rf = 0.36 (EtOAc:petroleum ether, 
1:1); 1H NMR (400 MHz, Acetone-d6) δ 8.22–8.15 (m, 1H), 8.15–8.12 (m, 1H), 7.91–7.86 (m, 1H), 7.84–7.80 (m, 
1H), 7.77–7.70 (m, 2H), 7.57 (t, J = 7.8 Hz, 1H), 7.30–7.22 (m, 2H), 5.10–5.01 (m, 1H), 3.71 (s, 3H), 3.66 (s, 3H), 
3.08–2.90 (m, 2H); 13C NMR (101 MHz, Acetone-d6) δ 172.0, 171.6, 167.2, 164.9, 141.1, 137.5 (d, J = 3.4 Hz), 
135.8, 130.8, 130.0, 129.9 (d, J = 8.2 Hz), 127.2, 126.6, 116.6 (d, J = 21.6 Hz), 52.7, 52.1, 50.5, 36.7; ESI-HRMS 
calcd for C19H18FNNaO5 (M + Na)+ 382.1061, found 382.1053.
25 was synthesised from 25e (25 mg, 0.07 mmol) according to the general ester hydrolysis procedure to give 
20 mg (87%) of a white foam: tR = 10.03 min (HPLC); 1H NMR (400 MHz, Acetone-d6) δ 8.18–8.10 (m, 2H), 7.89 
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(dd, J = 7.7, 1.1 Hz, 1H), 7.85–7.79 (m, 1H), 7.78–7.71 (m, 2H), 7.61–7.54 (m, 1H), 7.31–7.20 (m, 1H), 5.11–
5.02 (m, 1H), 3.10–2.94 (m, 2H); 13C NMR (101 MHz, Acetone-d6) δ 172.5, 172.3, 167.3, 163.6 (d, J = 245.2 Hz), 
141.1, 137.5 (d, J = 3.1 Hz), 135.9, 130.8, 130.0, 129.9 (d, J = 8.2 Hz), 127.2, 126.6, 116.6 (d, J = 21.7 Hz), 50.3, 36.5; 
ESI-HRMS calcd for C17H13FNO5 (M − H)− 330.0783, found 330.0796; [α]20D + 9.0° (c 0.2, MeOH).
(4′-Fluoro-[1,1′-biphenyl]-4-carbonyl)-L-aspartic acid (26). Dimethyl (4′-fluoro-[1,1′-biphenyl]-4-c
arbonyl)-L-aspartate (26e) was synthesised from (4-fluorophenyl)boronic acid (37 mg, 0.26 mmol) and 7e (81 mg, 
0.34 mmol) according to the general Suzuki coupling procedure. Purification by flash column chromatography 
(EtOAc:petroleum ether, 1:1) gave 71 mg (84%) of a white solid: Rf = 0.31 (EtOAc:petroleum ether, 1:1); 1H NMR 
(400 MHz, Acetone-d6) δ 8.10–8.04 (m, 1H), 8.00–7.95 (m, 2H), 7.80–7.72 (m, 4H), 7.30–7.22 (m, 2H), 5.09–5.02 
(m, 1H), 3.72 (s, 3H), 3.67 (s, 3H), 3.08–2.93 (m, 2H); 13C NMR (101 MHz, Acetone-d6) δ 172.1, 171.7, 166.9, 
163.8 (d, J = 245.6 Hz), 143.9, 137.2 (d, J = 3.1 Hz), 133.9, 129.9 (d, J = 8.2 Hz), 128.9, 127.7, 116.6 (d, J = 21.7 Hz), 
52.7, 52.1, 50.4, 36.7; ESI-HRMS calcd for C19H18FNNaO5 (M+Na)+ 382.1061, found 382.1056; [α]20D − 27.0° 
(c 0.2, MeOH).
26 was synthesised from 26e (56 mg, 0.15 mmol) according to the general ester hydrolysis procedure to give 
48 mg (94%) of a white solid: tR = 10.02 min (HPLC); 1H NMR (400 MHz, DMSO-d6) δ 12.58 (br s, 2H), 8.83–8.75 
(m, 1H), 8.02–7.92 (m, 2H), 7.85–7.75 (m, 4H), 7.39–7.28 (m, 2H), 4.83–4.74 (m, 1H), 2.93–2.69 (m, 2H); 13C 
NMR (101 MHz, DMSO-d6) δ 172.5, 171.7, 165.6, 161.0, 141.8, 135.6 (d, J = 3.1 Hz), 132.6, 128.9 (d, J = 8.3 Hz), 
128.0, 126.4, 115.8 (d, J = 21.4 Hz), 49.4, 35.8; ESI-HRMS calcd for C17H13FNO5 (M − H)− 330.0783, found 
330.0768; [α]20D + 1.0° (c 0.2, MeOH).
(6-(4-Fluorophenyl)picolinoyl)-L-aspartic acid (27). Dimethyl (6-(4-fluorophenyl)picolinoyl)- 
L-aspartate (27e) was synthesised from (4-fluorophenyl)boronic acid (40 mg, 0.28 mmol) and dimethyl 
(6-bromopicolinoyl)-L-aspartate (88 mg, 0.26 mmol) according to the general Suzuki coupling procedure. 
Purification by flash column chromatography (EtOAc:petroleum ether, 1:1) gave 81 mg (88%) of a pale yellow 
sticky oil: Rf = 0.62 (EtOAc); 1H NMR (400 MHz, Acetone-d6) δ 9.18–9.11 (m, 1H), 8.29–8.23 (m, 2H), 8.18–8.13 
(m, 1H), 8.12–8.07 (m, 2H), 7.35–7.26 (m, 2H), 5.13–5.04 (m, 1H), 3.74 (s, 3H), 3.69 (s, 3H), 3.11–3.04 (m, 
2H); 13C NMR (101 MHz, Acetone-d6) δ 172.0, 171.9, 164.7 (d, J = 247.5 Hz), 164.5, 155.7, 150.5, 139.8, 135.5 (d, 
J = 3.1 Hz), 130.0 (d, J = 8.5 Hz), 123.8, 121.4, 116.5 (d, J = 21.9 Hz), 52.9, 52.2, 49.7, 36.8; ESI-HRMS calcd for 
C18H17FN2NaO5 (M + Na)+ 383.1014, found 383.1011; [α]20D + 4.5° (c 0.2, MeOH).
27 was synthesised from 27e (70 mg, 0.19 mmol) according to the general ester hydrolysis procedure to give 
57 mg (88%) of a pale yellow solid: tR = 9.77 min (HPLC); 1H NMR (400 MHz, Acetone-d6) δ 11.25 (br s, 2H), 
9.27–9.16 (m, 1H), 8.35–8.21 (m, 2H), 8.21–8.07 (m, 3H), 7.34–7.22 (m, 2H), 5.13–5.03 (m, 1H), 3.19–3.01 (m, 
2H); 13C NMR (101 MHz, Acetone-d6) δ 172.6, 172.3, 164.7 (d, J = 247.3 Hz), 164.5, 155.6, 150.6, 139.7, 135.5 (d, 
J = 3.2 Hz), 129.9 (d, J = 8.5 Hz), 123.7, 121.4, 116.5 (d, J = 21.8 Hz), 49.5, 36.5; ESI-HRMS calcd for C16H12FN2O5 
(M − H)− 331.0736, found 331.0745; [α]20D + 19.0° (c 0.2, MeOH).
(4′-Methoxy-[1,1′-biphenyl]-3-carbonyl)-L-aspartic acid (28). Dimethyl (4′-methoxy-[1,1′
-biphenyl]-3-carbonyl)-L-aspartate (28a) was synthesised from (4-methoxyphenyl)boronic acid (43 mg, 
0.28 mmol) and 7e (88 mg, 0.26 mmol) according to the general Suzuki coupling procedure. Purification by flash 
column chromatography (EtOAc:petroleum ether, 1:1) gave 72 mg (75%) of a pale yellow sticky oil: Rf = 0.29 
(EtOAc:petroleum ether, 1:1); 1H NMR (400 MHz, Acetone-d6) δ 8.20–8.14 (m, 1H), 8.13–8.09 (m, 1H), 7.85–7.76 
(m, 2H), 7.67–7.60 (m, 2H), 7.57–7.50 (m, 1H), 7.08–7.02 (m, 2H), 5.11–5.01 (m, 1H), 3.85 (s, 3H), 3.71 (s, 3H), 
3.66 (s, 3H), 3.09–2.90 (m, 2H); 13C NMR (101 MHz, Acetone-d6) δ 172.1, 171.6, 167.3, 160.7, 141.9, 135.7, 133.4, 
130.4, 129.9, 129.0, 126.5, 126.2, 115.3, 55.7, 52.7, 52.1, 50.5, 36.7; ESI-HRMS calcd for C20H21NNaO6 (M + Na)+ 
394.1261, found 394.1268; [α]20D − 23.5° (c 0.2, MeOH).
28 was synthesised from 28e (64 mg, 0.17 mmol) according to the general ester hydrolysis procedure to give 
57 mg (97%) of a pale yellow solid: tR = 9.92 min (HPLC); 1H NMR (400 MHz, Acetone-d6) δ 11.15 (br s, 2H), 
8.16–8.08 (m, 2H), 7.87–7.82 (m, 1H), 7.82–7.76 (m, 1H), 7.68–7.61 (m, 2H), 7.56–7.50 (m, 1H), 7.09–7.01 (m, 
2H), 5.12–5.02 (m, 1H), 3.85 (s, 3H), 3.13–2.95 (m, 2H); 13C NMR (101 MHz, Acetone-d6) δ 172.5, 172.3, 167.5, 
160.7, 141.9, 135.8, 133.4, 130.3, 129.9, 129.0, 126.4, 126.2, 115.3, 55.7, 50.3, 36.5; ESI-HRMS calcd for C18H16NO6 
(M − H)− 342.0983, found 342.0989; [α]20D − 1.5° (c 0.2, MeOH).
(6-(4-Methoxyphenyl)picolinoyl)-L-aspartic acid (29). Dimethyl (6-(4-methoxyphenyl)picol-
inoyl)-L-aspartate (29e) was synthesised from (4-methoxyphenyl)boronic acid (42 mg, 0.28 mmol) and dime-
thyl (6-bromopicolinoyl)-L-aspartate (86 mg, 0.25 mmol) according to the general Suzuki coupling procedure. 
Purification by flash column chromatography (EtOAc:petroleum ether, 1:1) gave 63 mg (67%) of a milky sticky 
oil: Rf = 0.25 (EtOAc:petroleum ether, 1:1); 1H NMR (400 MHz, Acetone-d6) δ 9.20–9.11 (m, 1H), 8.20–8.13 
(m, 2H), 8.11–7.98 (m, 3H), 7.12–7.04 (m, 2H), 5.12–5.04 (m, 1H), 3.89 (s, 3H), 3.74 (s, 3H), 3.69 (s, 3H), 3.13–
3.01 (m, 2H); 13C NMR (101 MHz, Acetone-d6) δ 171.94, 171.93, 164.6, 162.2, 156.5, 150.3, 139.4, 131.4, 129.2, 
123.1, 120.6, 115.1, 55.8, 52.8, 52.2, 49.7, 36.8; ESI-HRMS calcd for C19H20N2NaO6 (M + Na)+ 395.1214, found 
395.1217; [α]20D + 4.0° (c 0.2, MeOH).
29 was synthesised from 29e (54 mg, 0.14 mmol) according to the general ester hydrolysis procedure to give 
48 mg (96%) of a pale yellow foam: tR = 9.69 min (HPLC); 1H NMR (400 MHz, Acetone-d6) δ 11.26 (br s, 2H), 
9.29–9.16 (m, 1H), 8.22–8.13 (m, 2H), 8.11–7.99 (m, 3H), 7.12–7.00 (m, 2H), 5.13–5.01 (m, 1H), 3.88 (s, 3H), 
3.24–3.01 (m, 2H); 13C NMR (101 MHz, Acetone-d6) δ 172.7, 172.4, 164.7, 162.1, 156.4, 150.4, 139.4, 131.5, 129.1, 
123.0, 120.6, 115.1, 55.8, 49.4, 36.6; ESI-HRMS calcd for C17H15N2O6 (M − H)− 343.0936, found 343.0932; [α]20D 
+ 18.0° (c 0.2, MeOH).
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(4′-(Trifluoromethoxy)-[1,1′-biphenyl]-3-carbonyl)-L-aspartic acid (30). Dimethyl (4′-(trifluo-
romethoxy)-[1,1′-biphenyl]-3-carbonyl)-L-aspartate (30e) was synthesised from (4-(trifluoromethoxy)phenyl)
boronic acid (58 mg, 0.28 mmol) and 7e (87 mg, 0.25 mmol) according to the general Suzuki coupling procedure. 
Purification by flash column chromatography (EtOAc:petroleum ether, 2:3) gave 77 mg (72%) of a pale yellow 
solid: Rf = 0.40 (EtOAc:petroleum ether, 1:1); 1H NMR (400 MHz, Acetone-d6) δ 8.23–8.18 (m, 1H), 8.18–8.15 
(m, 1H), 7.94–7.90 (m, 1H), 7.89–7.85 (m, 1H), 7.85–7.80 (m, 2H), 7.63–7.57 (m, 1H), 7.49–7.43 (m, 2H), 5.11–
5.02 (m, 1H), 3.72 (s, 3H), 3.66 (s, 3H), 3.09–2.91 (m, 2H); 13C NMR (101 MHz, Acetone-d6) δ 172.0, 171.6, 
167.1, 140.7, 140.4, 135.9, 131.0, 130.1, 129.7, 127.6, 126.8, 122.4, 52.7, 52.1, 50.5, 36.7; ESI-HRMS calcd for 
C20H18F3NNaO6 (M + Na)+ 448.0978, found 448.0981; [α]20D − 22.5° (c 0.2, MeOH).
30 was synthesised from 30e (68 mg, 0.16 mmol) according to the general ester hydrolysis procedure to give 
60 mg (94%) of a white solid: tR = 11.38 min (HPLC); 1H NMR (400 MHz, Acetone-d6) δ 11.21 (br s, 2H), 8.21–
8.18 (m, 1H), 8.18–8.11 (m, 1H), 7.97–7.90 (m, 1H), 7.90–7.80 (m, 3H), 7.64–7.57 (m, 1H), 7.49–7.42 (m, 2H), 
5.12–5.02 (m, 1H), 3.11–2.94 (m, 2H); 13C NMR (101 MHz, Acetone-d6) δ 172.5, 172.3, 167.2, 149.7, 140.7, 140.4, 
136.1, 130.9, 130.1, 129.7, 127.6, 126.8, 122.4, 50.4, 36.5; ESI-HRMS calcd for C18H13F3NO6 (M − H)− 396.0700, 
found 396.0716; [α]20D − 1.0° (c 0.2, MeOH).
(6-(4-(Trifluoromethoxy)phenyl)picolinoyl)-L-aspartic acid (31). Dimethyl (6-(4-(trifluorometh-
oxy)phenyl)picolinoyl)-L-aspartate (31e) was synthesised from (4-(trifluoromethoxy)phenyl)boronic acid 
(60 mg, 0.29 mmol) and dimethyl (6-bromopicolinoyl)-L-aspartate (86 mg, 0.25 mmol) according to the general 
Suzuki coupling procedure. Purification by flash column chromatography (EtOAc:petroleum ether, 1:2) gave 
76 mg (72%) of a milky sticky oil: Rf = 0.38 (EtOAc:petroleum ether, 1:1); 1H NMR (400 MHz, Acetone-d6) δ 
9.19–9.11 (m, 1H), 8.36–8.31 (m, 2H), 8.23–8.18 (m, 1H), 8.15–8.11 (m, 2H), 7.53–7.47 (m, 2H), 5.13–5.06 (m, 
1H), 3.74 (s, 3H), 3.69 (s, 3H), 3.10–3.04 (m, 2H); 13C NMR (101 MHz, Acetone-d6) δ 172.0, 171.9, 164.4, 155.3, 
151.0, 150.6, 139.9, 138.2, 129.7, 124.2, 122.2, 121.9, 52.9, 52.2, 49.8, 36.7; ESI-HRMS calcd for C19H17F3N2NaO6 
(M + Na)+ 449.0931, found 449.0949; [α]20D + 2.0° (c 0.2, MeOH).
31 was synthesised from 31e (65 mg, 0.15 mmol) according to the general ester hydrolysis procedure to give 
58 mg (95%) of a white solid: tR = 10.98 min (HPLC); 1H NMR (400 MHz, Acetone-d6) δ 11.14 (br s, 2H), 9.25–
9.18 (m, 1H), 8.37–8.30 (m, 2H), 8.24–8.17 (m, 1H), 8.17–8.10 (m, 2H), 7.51–7.45 (m, 2H), 5.12–5.03 (m, 1H), 
3.21–3.00 (m, 2H); 13C NMR (101 MHz, Acetone-d6) δ 172.6, 172.3, 164.4, 155.2, 151.0, 150.7, 139.9, 138.2, 129.7, 
124.0, 122.1, 121.8, 49.5, 49.4, 36.5; ESI-HRMS calcd for C17H12F3N2O6 (M − H)− 397.0653, found 397.0665; 
[α]20D + 14.0° (c 0.2, MeOH).
(6-(4-(2,2,2-Trifluoroethoxy)phenyl)picolinoyl)-L-aspartic acid (32). Diethyl (6-chloropicolinoyl)- 
L-aspartate (32a) was synthesised from 6-chloropicolinic acid (615 mg, 3.90 mmol) and diethyl L-aspartate hydro-
chloride (679 mg, 3.01 mmol) according to the general amide coupling procedure. Purification by flash column chro-
matography (EtOAc:petroleum ether, 1:3) gave 840 mg (85%) of an orange oil: Rf = 0.31 (EtOAc:petroleum ether, 1:1); 
1H NMR (400 MHz, Acetone-d6) δ 8.73 (d, J = 7.5 Hz, 1H), 8.13–8.05 (m, 2H), 7.70 (dd, J = 7.4, 1.4 Hz, 1H), 5.07–4.99 
(m, 1H), 4.28–4.07 (m, 4H), 3.12–2.96 (m, 2H), 1.24 (t, J = 7.1 Hz, 3H), 1.23 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, 
Acetone-d6) δ 171.2, 171.1, 163.1, 151.2, 150.7, 141.9, 128.3, 122.1, 62.1, 61.3, 49.9, 36.9, 14.5, 14.4.
A Schlenck flask under an argon atmosphere was charged with Pd-XPhos-G4 (8 mg, 0.01 mmol), XPhos 
(9 mg, 0.02 mmol), diboronic acid (181 mg, 2.02 mmol), and KOAc (198 mg, 2.02 mmol). The flask was evacu-
ated and backfilled with argon, before addition of degassed EtOH (7 mL) and 1-chloro-4-(2,2,2-trifluoroethoxy)
benzene (141 mg, 0.67 mmol, prepared according to21). The flask was evacuated and backfilled with argon and 
stirred at 80 °C until the reaction turned yellow (30 min). Degassed aqueous K2CO3 (1.8 M, 1.1 mL) and 32a 
(222 mg, 0.67 mmol) dissolved in degassed EtOH (1 mL) were added, and the flask was once again evacuated and 
backfilled with argon and stirred at 80 °C for 16 hours. After completion, the reaction was cooled to rt, diluted 
with water and extracted with EtOAc (x3). The organic phases were combined, washed with brine, dried over 
Na2SO4 and concentrated in vacuo. The residue was purified by flash column chromatography (EtOAc:petroleum 
ether:AcOH, 1:2:0→99:0:1) to give 73 mg (25%) of (S)-4-ethoxy-4-oxo-2-(6-(4-(2,2,2-trifluoroethoxy)phenyl)
picolinamido)butanoic acid (32b) as a brown sticky solid: Rf = 0.22 (EtOAc + 1% AcOH); 1H NMR (400 MHz, 
Acetone-d6) δ 9.16 (d, J = 8.5 Hz, 1H), 8.25–8.20 (m, 2H), 8.15–8.09 (m, 1H), 8.09–8.03 (m, 2H), 7.25–7.17 (m, 
2H), 5.06 (dt, J = 8.5, 5.3 Hz, 1H), 4.77 (q, J = 8.6 Hz, 2H), 4.15 (q, J = 7.1 Hz, 2H), 3.07 (qd, J = 16.7, 5.3 Hz, 
2H), 1.22 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, Acetone-d6) δ 172.4, 172.0, 171.5, 164.6, 159.6, 156.0, 150.4, 
139.6, 133.2, 129.3, 122.1 (d, J = 238.1 Hz), 116.1, 66.2 (d, J = 35.1 Hz), 61.3, 49.6, 37.1, 14.5; ESI-MS m/z 439.1 
(M − H)−; [α]20D − 0.5° (c 0.2, MeOH).
32 was synthesised from 32b (40 mg, 0.09 mmol) according to the general ester hydrolysis procedure to give 
29 mg (77%) of a white solid: tR = 10.84 min (HPLC); 1H NMR (400 MHz, Acetone-d6) δ 11.24 (br s, 2H), 9.21 (d, 
J = 8.4 Hz, 1H), 8.26–8.18 (m, 2H), 8.11 (dd, J = 8.7, 4.2 Hz, 1H), 8.09–8.02 (m, 2H), 7.26–7.14 (m, 2H), 5.11–5.01 
(m, 1H), 4.77 (q, J = 8.6 Hz, 2H), 3.21–3.00 (m, 2H); 13C NMR (101 MHz, Acetone-d6) δ 172.6, 172.4, 164.6, 
159.6, 156.0, 150.5, 139.5, 133.2, 129.4, 124.9 (q, J = 276.5 Hz), 123.3, 121.0, 116.1, 66.2 (q, J = 35.1 Hz), 49.5, 36.6; 
ESI-HRMS calcd for C18H14F3N2O6 (M − H)− 411.0809, found 411.0812; [α]20D + 29.9° (c 0.2, MeOH).
(6-(4-Propoxyphenyl)picolinoyl)-L-aspartic acid (33). 1-Bromo-4-propoxybenzene (33a) was synthe-
sised from 4-bromophenol (250 mg, 1.44 mmol) and 1-iodopropane (0.45 mL, 4.61 mmol) according to the gen-
eral alkylation procedure. Purification by flash column chromatography (petroleum ether) gave 248 mg (80%) of a 
clear oil: Rf = 0.62 (EtOAc:petroleum ether, 1:6); 1H NMR (400 MHz, Acetone-d6) δ 7.44–7.38 (m, 2H), 6.92–6.86 
(m, 2H), 3.94 (t, J = 6.5 Hz, 2H), 1.83–1.70 (m, 2H), 1.01 (t, J = 7.4 Hz, 3H); 13C NMR (101 MHz, Acetone-d6) δ 
159.5, 133.0, 117.5, 112.8, 70.4, 23.2, 10.7.
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A Schlenck flask under an argon atmosphere was charged with Pd-XPhos-G4 (4 mg, 1 mol%), XPhos (6 mg, 
2 mol%), diboronic acid (135 mg, 1.50 mmol), and KOAc (147 mg, 1.50 mmol). The flask was evacuated and 
backfilled with argon, before addition of degassed EtOH (2.5 mL) and 33a (114 mg, 0.53 mmol). The flask was 
evacuated and backfilled with argon and stirred at 80 °C until the reaction turned orange (80 min). Degassed 
aqueous K2CO3 (1.8 M, 0.85 mL) and dimethyl (6-chloropicolinoyl)-L-aspartate (151 mg, 0.50 mmol) dissolved 
in degassed EtOH (0.25 mL) were added, and the flask was once again evacuated and backfilled with argon and 
stirred at 80 °C for 3 hours. After completion, the reaction was cooled to rt, diluted with water and extracted 
with EtOAc (x3). The organic phases were combined, washed with brine, dried over Na2SO4, and concentrated 
in vacuo. The residue was purified by flash column chromatography to give a mixture of methyl and ethyl esters 
of (6-(4-propoxyphenyl)picolinoyl)-L-aspartic acid after trans-esterification with the reaction solvent. The crude 
was therefore used directly in the hydrolysis following the general procedure to give 27 mg (15% over two steps) 
of 33 as a sticky pale yellow foam: tR = 11.09 min (HPLC); 1H NMR (400 MHz, Acetone-d6) δ 10.89 (br s, 2H), 9.22 
(d, J = 8.4 Hz, 1H), 8.19–8.10 (m, 2H), 8.10–7.99 (m, 3H), 7.09–7.01 (m, 2H), 5.06 (dt, J = 8.6, 5.1 Hz, 1H), 4.04 (t, 
J = 6.5 Hz, 2H), 3.20–2.97 (m, 2H), 1.88–1.72 (m, 2H), 1.04 (t, J = 7.4 Hz, 3H); 13C NMR (101 MHz, Acetone-d6) 
δ 172.6, 172.4, 164.7, 161.6, 156.5, 150.4, 139.4, 131.3, 129.1, 123.0, 120.5, 115.6, 70.3, 49.4, 36.6, 23.3, 10.7; 
ESI-HRMS calcd for C19H19N2O6 (M − H)− 371.1249, found 371.1240; [α]20D + 49.5° (c 0.2, MeOH).
Kinetic aqueous solubility. Duplicates of a 200 μM solution of the dicarboxylic acids were prepared from 
0.01 M PBS7.4 and a 10 mM stock solution in DMSO. The samples were incubated in an Eppendorf® Thermomixer 
(25 °C, 800 rpm) for 24 h. Afterwards, the samples were centrifuged for 5 min at 11,000 rpm and the superna-
tant was filtered (0.45 μm PTFE membrane) before analysis by HPLC. The solubility was calculated based on a 
concentration-absorption curve.
Chemical stability. Triplicates of a 50 μM solution of the test compounds were prepared from 0.01 M PBS7.4 
and a 10 mM stock solution in DMSO. The samples were incubated in an Eppendorf® Thermomixer (37 °C, 
650 rpm). The samples were briefly vortexed and 50 μL aliquots were withdrawn at the time points 0 h, 24 h, 48 h 
etc. and analysed immediately on UPLC. The chemical stability in PBS7.4 was determined at every time point in 
percentage relative to the 0 h time point.
Stability in simulated gastric and intestinal fluids. FaSSIF, FeSSGF and FaSSGF were prepared in 
accordance to the manufacturers procedure, Biorelevant.com. Triplicates of a 50 μM solution of the test com-
pounds were prepared from a 10 mM stock solution in DMSO diluted with FaSSGF/FaSSIF/FeSSIF. The samples 
were incubated in an Eppendorf® Thermomixer (37 °C, 650 rpm). Samples were withdrawn at 0 min and 120 min, 
centrifuged (10 min at 10,000 rpm) and the supernatant analysed by HPLC/UPLC. The stability was calculated 
based on peak area of a 0 point sample.
logD7.4 determination. A glass vial with screw cap (8 mL) was charged with test compound (40 μL, 10 mM 
in DMSO), PBS7.4 (0.01 M, 1980 μL), and 1-octanol (1980 μL). The vial was capped and sealed with parafilm and 
shaken at 700 rpm using an IKA® KS 125 basic shaker for 24 h at room temperature. The parafilm was removed 
and the sample was allowed to equilibrate for 1 h before analysis. 100 μL of the octanol phase was withdrawn and 
diluted 1:10 with MeOH(+0.1% formic acid)/MilliQ water (4:1, v/v) and analysed by HPLC/UPLC. The interface 
was removed and the PBS7.4 phase analysed directly by HPLC/UPLC. All analysis was performed in duplicates 
and logD values were calculated from the peak areas (mAU*min) and adjusted for difference in injection volume 
and concentration-absorption effects from the solvents, using two calibration points per compound per solvent, 
and dilution of the octanol phase. All compounds were analysed in triplicates.
Metabolic stability. Microsomal stability was studied in mouse liver microsomes (0.5 mg/mL) at a final test 
compound concentration of 1 μM and performed in triplicates in accordance to the published protocol22. In short: 
Prewarmed (37 °C) 0.1 M PBS7.4, 10 mM NADPH in PBS7.4 and test compound (1 mM in DMSO) were added to 
an Eppendorf® Tube. The samples were incubated for 5 min at 37 °C before addition of newly thawned micro-
somes. The samples were mixed by gentle vortexing and incubated for 1 h at 37 °C, 300 rpm in an Eppendorf® 
Thermomixer. Samples were quenched by addition of ice-cold MeOH/MeCN (1:1) and centrifuged for 5 min at 
10,000 g. The supernatant was transferred to HPLC vials and stored in the freezer until analysis by HPLC/UPLC. 
The metabolic stability was calculated based on a 0 min sample. All compounds were analysed in triplicates.
Molecular biology, cell culture, and transfection. Receptor constructs for mSUCNR1 and hSUCNR1 
were bought from Origene and cloned into the eukaryotic expression vector pCMV-Tag(2B) (Stratagene).
HEK-293 cells were cultured in Dulbecco’s modified Eagle’s medium 1885 (DMEM) supplemented with 10% 
fetal calf serum, 100 units/mL penicillin, and 100 μg/mL streptomycin. Transient transfection of the HEK-293 
cells was done with Lipofectamine-2000 according to manufacturer’s protocol. Cells were supplemented with 
fresh medium after 5 h.
IP3 turnover assay. 96-well plates were coated with poly-D-lysine and HEK-293 cells were plated (35.000 
cells/well). Cells were transfected for 5 h the following day and subsequently incubated O/N with 0.5 μCi/mL 
myo[3H]inositol (Perkin Elmer) in 100 μL growth medium. On day 3 cells were washed with 200 µL HBSS/well 
(Gibco, Life Technologies) followed by a pre-incubation (30 min, 37 °C) with 100 µL HBSS supplemented with 
10 mM LiCl. Cells were stimulated with ligand (120 min, 37 °C) and lysed with 50 µL 10 mM formic acid (30 min 
on ice). In a white 96 well plate 20 µL cell extracts and 80 µL 1:8 diluted YSi scintillation beads (Perkin Elmer) were 
mixed. The plate was spun down, and a Packard Top Count NXT counter recorded light emission (scintillation) 
after an 8 h delay.
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Automated Ligand-guided Backbone Ensemble Receptor Optimization protocol (ALiBERO). 
ALiBERO is an iterative sampling-selection protocol for receptor optimisation that relies on the use of ligand infor-
mation for selecting the best-performing receptor conformations19. Homology models of the mouse SUCNR1 
receptor were constructed according to Trauelsen et al.4 and loaded into ICM (Molsoft L.L.C., San Diego, CA, USA). 
The structure was converted into an ICM object, thereby assigning protein atom types, optimising hydrogens and 
His, Pro, Asn, Gly and Cys side-chain conformations. The explored chemical compounds were used as a training 
set by dividing all compounds into an active (EC50 ≤ 10 µM) and an inactive (EC50 > 10 µM) group, consisting of 25 
compounds each. For a list of all compounds used in the optimisation protocol, see Table S1. ALiBERO was per-
formed using the prepared receptor structure and ligand training set as input. Binding site residues were manually 
selected based on proximity to the position of MRS2500 in the superimposed structure of the P2Y1 receptor (PDB 
4XNW). 100 elastic network normal mode analysis derived conformers were built in order to recreate backbone and 
side-chain flexibility (T = 300 K). Next, a flexible-ligand static-receptor small-scale virtual screening was performed 
on each of the receptor conformers, from which several pockets were selected for the following generation. The 
ligand and decoy molecules were docked into mSUCNR1, represented as pre-calculated potential grids and then 
sorted according to their ICM VLS scores. The maximum number of complementary pockets for each generation 
was set to 5 with a maximum of 10 generations. Receptor models were selected based on their combined screening 
performance, as determined by the normalised square root area under the curve, NSQ_AUC. After each round of 
virtual screening, an all-atom Monte Carlo side-chain refinement was performed to account for induced-by-ligand 
changes. NSQ_AUC values were calculated according to Katritch et al.16.
The optimised model ensemble was validated in a virtual ligand screening with an external test set, con-
sisting of the 25 active compounds used in the ALiBERO optimisation and 1247 decoy molecules that were 
selected in a similarity search with a Daylight-type fingerprint threshold of Tc > 0.6 with the active compound 3 
as query molecule and subsequent structural clustering with a Tc threshold of 0.15. The test set was docked into 
the best-performing receptor ensemble from generation 10 of the ALiBERO refinement, using ICM 4D docking. 
The ROC-plot for the combined performance of the optimised receptor ensemble was computed by taking the 
best ICL VLS docking score of the receptor models for each docked compound.
Data availability. The datasets generated and analysed during the current study are available from the cor-
responding author on reasonable request.
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